US20040115221A1 - Intracellular delivery vehicles - Google Patents
Intracellular delivery vehicles Download PDFInfo
- Publication number
- US20040115221A1 US20040115221A1 US10/627,452 US62745203A US2004115221A1 US 20040115221 A1 US20040115221 A1 US 20040115221A1 US 62745203 A US62745203 A US 62745203A US 2004115221 A1 US2004115221 A1 US 2004115221A1
- Authority
- US
- United States
- Prior art keywords
- cell
- bacterium
- cytolysin
- coli
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003834 intracellular effect Effects 0.000 title abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 86
- 241000894006 Bacteria Species 0.000 claims abstract description 84
- 210000004027 cell Anatomy 0.000 claims abstract description 79
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 36
- 108010056995 Perforin Proteins 0.000 claims abstract description 30
- 102000004503 Perforin Human genes 0.000 claims abstract description 30
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 8
- 241000206602 Eukaryota Species 0.000 claims abstract description 3
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 3
- 241000588724 Escherichia coli Species 0.000 claims description 81
- 210000000172 cytosol Anatomy 0.000 claims description 54
- 101710198693 Invasin Proteins 0.000 claims description 15
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 14
- 210000003934 vacuole Anatomy 0.000 claims description 12
- 230000000890 antigenic effect Effects 0.000 claims description 10
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 7
- 230000009089 cytolysis Effects 0.000 claims description 7
- 108700027766 Listeria monocytogenes hlyA Proteins 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000000242 pagocytic effect Effects 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000006461 physiological response Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 64
- 230000000813 microbial effect Effects 0.000 abstract description 13
- 102000039446 nucleic acids Human genes 0.000 abstract description 9
- 108020004707 nucleic acids Proteins 0.000 abstract description 9
- 150000007523 nucleic acids Chemical class 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 5
- 108091005461 Nucleic proteins Proteins 0.000 abstract description 4
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- 101710164436 Listeriolysin O Proteins 0.000 description 79
- 210000002540 macrophage Anatomy 0.000 description 61
- 108010058846 Ovalbumin Proteins 0.000 description 51
- 229940092253 ovalbumin Drugs 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 49
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 29
- 210000000612 antigen-presenting cell Anatomy 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108010005774 beta-Galactosidase Proteins 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 21
- 239000000427 antigen Substances 0.000 description 20
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 17
- 238000012545 processing Methods 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 210000000680 phagosome Anatomy 0.000 description 14
- 230000030741 antigen processing and presentation Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000002238 attenuated effect Effects 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 102000043129 MHC class I family Human genes 0.000 description 11
- 108091054437 MHC class I family Proteins 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 241000186779 Listeria monocytogenes Species 0.000 description 10
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 229930040373 Paraformaldehyde Natural products 0.000 description 7
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 229920002866 paraformaldehyde Polymers 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000002949 hemolytic effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 102000053642 Catalytic RNA Human genes 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 101150024289 hly gene Proteins 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 108091092562 ribozyme Proteins 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241001529936 Murinae Species 0.000 description 4
- 241000607762 Shigella flexneri Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 101150118377 tet gene Proteins 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- GMKMEZVLHJARHF-UHFFFAOYSA-N 2,6-diaminopimelic acid Chemical compound OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001400 expression cloning Methods 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- UYYRDZGZGNYVBA-VPXCCNNISA-N (2s,3r,4s,5r,6r)-2-[2-chloro-4-[3-(3-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Cl)C(O)=CC=2)C=C1Cl UYYRDZGZGNYVBA-VPXCCNNISA-N 0.000 description 2
- 101710092462 Alpha-hemolysin Proteins 0.000 description 2
- 101710197219 Alpha-toxin Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000701867 Enterobacteria phage T7 Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101710124951 Phospholipase C Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 239000002776 alpha toxin Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- -1 semisolid Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 108010075210 streptolysin O Proteins 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010065693 Clostridium perfringens theta-toxin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 101100301239 Myxococcus xanthus recA1 gene Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101100123346 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) hh2a gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000884 anti-protozoa Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 101150026598 deoC1 gene Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000013227 macrophage apoptotic process Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 101150015201 rbsR gene Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the field of this invention is microbial-based intracellular delivery of agents to eukaryotic cells.
- retroviral vectors have been used for the delivery and subsequent expression of DNA in host cells (5-7)
- bacterial vectors have been exploited primarily for the delivery of antigenic proteins and more recently adapted for the delivery of DNA to mammalian cells (8-12).
- the invention provides methods and compositions relating to intracellular delivering of agents to eukaryotic cells.
- the compositions include microbial delivery vehicles such as nonvirulent bacteria comprising a first gene encoding a nonsecreted foreign cytolysin operably linked to a heterologous promoter and a second gene encoding a different foreign agent.
- the bacteria may be variously invasive to the target cell, autolysing within target cell endosomes and preferably, a laboratory strain of E. coli .
- the cytolysin may lack a functional signal sequence, and is preferably a listeriolysin.
- the foreign agent may be a nucleic acid or protein, and is frequently bioactive in and therapeutic to the target eukaryote.
- the invention provides eukaryotic cells comprising the subject nonvirulent bacteria and nonhuman eukaryotic host organisms comprising such cells.
- the invention also provides methods for introducing foreign agents into eukaryotic cells comprising the step of contacting the cell in vivo or in vitro with the subject bacteria under conditions whereby the agent enters the cell.
- the bacterium is endocytosed into a vacuole of the cell, undergoes lysis and the cytolysin mediates transfer of the agent from the vacuole to the cytosol of the cell.
- FIG. 1 Presentation of SL8/K b complex to B3Z T-cells.
- FIGS. 2A and 2B Time requirement for presentation of SL8/K b complex.
- the subject bacteria comprise a first gene encoding a nonsecreted foreign cytolysin operably linked to a heterologous promoter.
- cytolysins may be used so long as the cytolysin is not significantly secreted by the microbe and facilitates cytosolic delivery of the foreign agent as determined by the assays described below.
- Exemplary cytolysins include phospholipases (see, e.g., Camilli, A., et at., J. Exp. Med.
- LLO listeriolysin O
- SLO streptolysin O
- PFO perfringolysin 0
- cytolysins may be advantageously used.
- listeriolysin O exhibits greater pore-forming ability at mildly acidic pH (the pH conditions within the phagosome), thereby facilitating delivery of the liposome contents to the cytoplasm (see, e.g., Portnoy, et al., Infect. Immun. 60:2710-2717 (1992)).
- natural cytolysins are readily modified to generate mutants which are screened in the assays described below or otherwise known in the art (e.g. Awad M M, et al., Microb Pathog. 1997, 22(5): 275-284) desired activity modifications.
- the screening assays measure the ability of a candidate cytolysin to confer on a bacterium the ability to render a target cell vacuole permeable to a label (e.g., a fluorescent or radioactive label) that is contained in the vacuole.
- a label e.g., a fluorescent or radioactive label
- the invention provides mutations in natural cytolysin wherein highly conserved cysteine residues (e.g., cysteine 460 in PFO, cysteine 486 in LLO) are replaced by conservative amino acid substitutions which are not subject to reduction in order to prepare oxidation/reduction-insensitive cytolysin mutants which exhibit improved lytic activity.
- mutant cytolysins are selected from naturally occurring mutants by, for example, identifying bacteria which contain cytolysins that are capable of lysing cells over a narrow pH range, preferably the pH range which occurs in phagosomes (pH 5.0-6.0), or under other conditions (e.g., ionic strength) which occur in the targeted phagosomes.
- Nonsecreted cytolysins may be provided by various mechanisms, e.g. absence of a functional signal sequence, a secretion incompetent microbe, such as microbes having genetic lesions (e.g. a functional signal sequence mutation), or poisoned microbes, etc.
- the bacteria also comprise a second gene encoding a foreign agent different from the cytolysin, and the subject methods may be used to deliver a wide variety of such foreign agents for a variety of applications, including diagnosis, therapy including prophylactics such as immunizations (see, e.g. HIV vaccine, Table 1) and treatments such as gene therapy (especially of single gene disorders amenable to localized treatment, see Table 1, below), biosynthesis, etc.; essentially any agent that the microbial host can be engineered to produce.
- the agent is largely retained by the microbe until lysis within the target cell vacuole.
- the first and second genes may be the same, i.e.
- the same nucleic acid encodes both the cytolysin and the foreign agent.
- the foreign agent is expressed in frame with the cytolysin as a fusion protein.
- the microbes are engineered to deliver libraries of agents for screening, e.g. Tenson T, et al., J Biol Chem 1997 Jul. 11;272(28):17425-17430.
- nucleic acid-based agents may be delivered, including expression vectors, probes, primers, antisense nucleic acids, knockout/in vectors, ribozymes, etc.
- the subject bacteria are used to deliver nucleic acids which provide templates for transcription or translation or provide modulators of transcription and/or translation by hybridizing to selected endogenous templates, see, e.g. U.S. Pat. No. 5,399,346 for a non-limiting list of genes that can be administered using gene therapy and diseases that can be treated by gene therapy.
- polynucleotide agents may provide a coding region operably linked to a transcriptional regulatory region functional in a target mammalian cell, e.g.
- RNA virus infected cells are targeted by microbes delivering viral RNA-specific ribozymes, e.g. HIV-infected T-cells, leukemia virus infected leukocytes, hepatitis C infected liver cells.
- labeled probes are delivered which effect in situ hybridization-based diagnostics.
- polypeptide-based agents may also be delivered, including antibiotics, insecticides, fungicides, anti-viral agents, anti-protozoan agents, enzymes, anti-cancer agents (e.g. cyclin dependent kinase (CDK) inhibitors such as P16, P21 or P27), antibodies, anti-inflammatory peptides, transcription factors, antigenic peptides, etc.
- CDK cyclin dependent kinase
- Exemplary therapeutically active polypeptides which can be delivered by the subject invention are described in Nature Biotech 16(2), entire issue, etc.
- the invention provides for the delivery to antigen-presenting cells of antigenic polypeptides which are presented in association with MHC proteins.
- both nucleic acids and proteins are delivered together contemporaneously, in the same administration or in the same microbe.
- the nucleic acids and proteins can act in concert, e.g. an integrating vector and an integrase, and RNA and a reverse transcriptase, a transposon and a transposase, etc.
- microbes may be selected for, or engineered to contain, biosynthetic machinery to produce any microbiologically producible agent compatible with the subject methods (e.g. sufficiently microbe impermeant to provide effective delivery to the target cell).
- Preferred such agents are those that are contraindicated for convenient direct (e.g. oral) administration, because of, for example, gut inactivation, toxicity, intolerance, impermeability, etc.
- agents providing significant toxicity to the microbial host find use so long as an effective amount of the agent may be loaded (by synthesis) or maintained in the microbe (see, e.g. LLO toxicity, below).
- nonvirulent, non-pathogenic bacteria may be used; preferred microbes are relatively well characterized strains, particularly laboratory strains of E. coli , such as MC4100, MC1061, DH5 ⁇ , etc.
- Other bacteria that can be engineered for the invention include well-characterized, nonvirulent, non-pathogenic strains of Listeria monocytogenes, Shigella flexneri , mycobacterium, Salmonella, Bacillus subtilis , etc.
- the bacteria are attenuated to be nonreplicative, nonintegrative into the host cell genome, and/or non-motile inter- or intra-cellularly.
- suitable means for microbial attenuation are known in the art.
- the bacteria are dead or non-viable prior to endocytosis by the target cell or administration to the target organism, obviating any microbial growth or metabolism in the target cell.
- suitable means for killing or rendering the bacteria nonviable are known in the art, including fixation with organic solvents such as methanol, UV irradiation, heat, freeze-drying, etc.
- Preferred methods preserve the ability of the microbial membrane and/or wall to retain the cytolysin and the foreign agent.
- the first and second genes are sufficiently expressed to load the microbe with an effective amount of the cytolysin and foreign agent prior to microbial cell death.
- the bacteria contain (i.e. are loaded by expression within the bacteria with) with from about ten to one thousand, preferably from about one hundred to one thousand cytolysin molecules per bacterium.
- the microbes of the invention can be used to deliver the foreign agent to virtually any target cell capable of endocytosis of the subject microbe, including phagocytic, non-phagocytic, pathogenic or diseased cells.
- target animal cells include epithelial cells, endothelial cells, muscle cells, liver cells, pancreatic cells, neural cells, fibroblasts, tumor cells, leukocytes such as macrophages, neutrophils, B-cells, T-cells, monocytes, etc., etc.
- the subject methods generally require microbial uptake by the target cell and subsequent lysis within the target cell vacuole (including phagosomes and endosomes).
- phagocytic target cells generally provide for microbial uptake and lysis, for many cell types, it is necessary to provide the bacteria with an invasin to facilitate or mediate uptake by the target cell and an autolysin to facilitate or mediate autolysis of the bacteria within the target cell vacuole.
- invasins and autolysins are known in the art. For example, both Sizemore et al. ( Science, 1995, 270:299-302) and Courvalin et al. ( C.R. Acad. Sci.
- Providing the advantage of delayed lysis are temperature-sensitive autolysins, time-sensitive autolysins (see, e.g. Chang et al., 1995, J Bact 177, 3283-3294; Raab et al., 1985, J Mol Biol 19, 95-105; Gerds et al., 1995, Mol Microbiol 17, 205-210) and addiction (poison/antidote) autolysins, (see e.g. Magnuson R, et al., 1996, J Biol Chem. 271(31), 18705-18710; Smith A S, et al., 1997, Mol Microbiol. 26(5), 961-970).
- Administration of the microbe to target cells may be in vitro or in vivo according to conventional methodologies.
- the methods generally involve growing the microbes, inducing the expression of the first and second genes, and contacting the target cells with an effective amount of bacteria sufficient to effect the desired activity of the foreign agent in the target cell.
- Immunofluorescense may be used to image and track the contents of the bacteria upon administration to the cells in vivo or in vitro.
- In vitro or ex vivo administration generally involves contacting the target cell with an effective amount of the microbes of the invention.
- Exemplary in vitro administrations are described and/or cited by reference below.
- In vitro applications include protein delivery (e.g. for functional determinations, toxin delivery to targeted cells in culture, half-life, degradation and localization determinations), nucleic acid delivery (e.g. DNA to transfected cell lines, genomic libraries to screen and identify specific antigens, i.e. expression cloning, etc.)
- In vivo administration generally involves administering a pharmaceutical composition containing a therapeutically effective amount of the microbes of the invention.
- the therapeutically effective amount is between about 1 ⁇ g and 100 mg/kg, preferably between about 1 ⁇ g and 1 mg/kg.
- the microbes are formulated into a pharmaceutical composition by combination with an appropriate pharmaceutically acceptable excipient in accordance with routine procedures known to one of ordinary skill in the art.
- the microbes may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
- the microbes may be formulated into preparations in solid, semisolid, or liquid form such as tablets, capsules, powders, granules, ointments, solutions, suppositories, and injections, in usual ways for topical, nasal, oral, parenteral, or surgical administration.
- Administration in vivo can be oral, mucosal, nasal, bronchial, parenteral, subcutaneous, intravenous, intra-arterial, intra-muscular, intra-organ, intra-tumoral, surgical or in general by any means typical of a gene therapy administration. Administration will be selected as is appropriate for the targeted host cells.
- Target cells may also be removed from the subject, treated ex vivo, and the cells then replaced into the subject.
- a K12 strain of E. coli is engineered with a signal sequence deficient LLO gene operably linked to the constitutive tet promoter for expressing the cytolysin in the bacterium and a second gene encoding a truncated BRCA1 cancer antigen, under regulatory control of a trc or tac promoter.
- the cytolysin and cancer antigen are expressed to maximum levels, the bacteria are then fixed with methanol, and the killed bacteria loaded with the cytolysin and cancer antigen are then injected into solid breast tumors in three weekly injections.
- CTL response cytotoxic T-cell response
- Table 1 analogous studies conducted in a variety of animals and animal cell types, both in vivo and in vitro, using a variety of agents, secretory deficient cytolysins, bacterial types and methods demonstrate consistent delivery of the agent to the target cell cytosol, as measured by agent activity, immunoassay, or other delivery monitoring assays described herein.
- TABLE 1 Microbial-Based Delivery Cytosol Target Cell Indication Agent Lysin Bacteria Administration Delivery transformed human acites tumor human tumor LLO E.
- Listeria monocytogenes is a bacterial pathogen that replicates within the cytosol of mammalian cells.
- L. monocytogenes has been used extensively as a model for the study of cell-mediated immunity and as a model pathogen for understanding the basis of intracellular pathogenesis (13, 14). Following internalization into host cells, bacteria are initially contained within host vacuoles then subsequently lyse these vacuoles to gain access to the cytosol. The ability of L. monocytogenes to lyse the vacuole and enter the cytosol is primarily mediated by listeriolysin O (LLO).
- LLO listeriolysin O
- LLO is a member of a family of related pore-forming cytolysins secreted by diverse species of gram positive bacteria (15). LLO encapsulated into pH-sensitive liposomes has been used as a vehicle to deliver co-encapsulated protein to the cytosol of macrophages (16). Moreover, purified LLO when mixed with foreign proteins and added to mammalian cells can mediate the delivery of protein to the cytosol and has been exploited for delivery to host cells both in vitro and in vivo (17-19). However, both of these methods require the purification of LLO and the protein to be delivered.
- Escherichia coli expressing cytoplasmic LLO can be used to efficiently deliver co-expressed proteins to the cytosol of macrophages.
- the utility of this system to deliver a large active protein to the cytosol was demonstrated by the delivery of E. coli ⁇ -galactosidase ( ⁇ -gal).
- OVA ovalbumin
- Plasmid pDP3615 was generated by PCR amplification of the hly gene encoding LLO lacking its secretion signal sequence (22). DNA sequences encoding mature LLO were first PCR amplified and cloned into pET29b (Novagen, Inc., Madison, Wis.) using oligonucleotide primer 5′-GGAATTCCATATGAAGGATGCATCTGCATTCAAT-3′ (SEQ ID NO:1) generating a NdeI restriction site at the 5′-end of the gene fragment and primer 5′-CGGGATCCTTATTATTCGATTGGATTATCTACT-3′ (SEQ ID NO:2) generating a BamHI restriction site at the 3′ end of the gene fragment.
- the DNA sequences encoding mature LLO along with the upstream translation initiation site found in pET29b were amplified using primer 5′-CGCGATATCCTCTAGAAATAATTTTG-3′ (SEQ ID NO:3) generating an EcoRI restriction site at the 5′ end of the gene fragment and the same primer used previously to generate a BamHI restriction site at the 3′ end of the gene fragment.
- the amplified fragment was ligated into pACYC184 (23) placing transcription of the mature hly gene under control of the tet gene promoter.
- Plasmid pDP3616 was generated by subcloning a NcoI-HindIII fragment containing DNA sequences encoding truncated OVA from plasmid pTrcHisC/OVA. The DNA fragment was ligated into the over-expression vector pET28a (Novagen, Inc., Madison, Wis.).
- Plasmid pDH70 was generated by PCR amplification of the promoterless lacZ gene in plasmid pTL61T (24) using oligonucleotide primers 5′-AGGCGTCGACGGTTAATACGACCGGGATCGAG-3′ (SEQ ID NO:4) and 5′-AGGCGTCGACAGGCCTTACGCGAAATACGGGCAGACATGG-3′ (SEQ ID NO: 5) generating SalI restriction sites at both the 5′ and 3′ ends of the fragment.
- the amplified fragment was ligated into pBluescript SK ⁇ (Stratagene, Inc., La Jolla, Calif.) placing transcription of the lacZ gene under control of a phage T7 promoter. Plasmid DNA was transferred to E.
- E. coli strains by transformation, using standard methods (25). E. coli strains were grown in Luria-Bertani (LB) medium. The strains were stored at ⁇ 70° C. in LB medium plus 40% glycerol. Antibiotics were used at the following concentrations: ampicillin, 100 ⁇ g/ml; chloramphenicol, 40 ⁇ g/ml; and kanamycin, 30 ⁇ g/ml.
- E. coli strains were inoculated from a LB agar plate into 2 mls of LB medium and grown overnight to stationary phase at 37° C. with aeration. Cultures were diluted 1:100 in 10 mls of LB medium in 250 ml flasks and grown 2 hours with aeration at 30° C. Target protein expression was induced by the addition of isopropyl- ⁇ -D-thiogalactopyranoside (IPTG) to 1 mM and growth continued until cultures reached an OD 600 of 0.5. Equivalent numbers of bacteria were centrifuged (14,000 ⁇ g) for 1 minute and washed once with phosphate buffered saline (PBS).
- IPTG isopropyl- ⁇ -D-thiogalactopyranoside
- Washed samples were suspended in Final Sample Buffer (0.0625M Tris pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue) boiled for 5 minutes and total cellular protein analyzed by polyacrylamide gel electrophoresis followed by staining with Coomassie Brilliant Blue.
- Final Sample Buffer (0.0625M Tris pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue
- Cell Culture Cell lines were maintained in RPMI 1640 medium or DMEM supplemented with 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, Utah), 2 mM glutamine, 1 mM pyruvate, 50 ⁇ M 2-mercaptoethanol, penicillin (200 units/ml), and streptomycin (200 ⁇ g/ml) at 37° C. in a 5% CO 2 /air atmosphere.
- the IC-21 and Raw 309 Cr.1 mouse macrophage cell lines were obtained from the American Type Culture Collection (ATCC, Rockford, Md.).
- the B3Z T-cell hybrid is a LacZ-inducible CD8 + T-cell hybridoma specific for OVA residues 257-264, SIINFEKL (SL8)(SEQ ID NO:6), presented on the murine K b MHC class I molecule (27, 28).
- OVA was detected by immunofluorescence as previously described (29) with the exception that polyclonal rabbit anti-OVA antibody (Calbiochem, San Diego, Calif.) and LRSC-conjugated donkey anti-rabbit IgG antibody (Jackson ImmunoResearch, West Grove, Pa.) were used for detection.
- Antigen Presentation Assays Presentation of SL8/K b complex to B3Z cells was determined as previously described (30). Briefly, E. coli were added to 1 ⁇ 10 5 antigen presenting cells (APCs) in each well of a 96-well microtiter plate. Following one hour of incubation at 37° C. in a 5% CO 2 /air atmosphere, extracellular bacteria were removed by washing three times with PBS and 1 ⁇ 10 5 B3Z T cells were added to each well in medium containing 100 ⁇ g/ml gentamicin. Following 15 hours of incubation at 37° C.
- APCs antigen presenting cells
- OVA is not toxic to E. coli and can be readily expressed to high levels (32).
- a plasmid encoding truncated (32 kD) OVA was transformed into E. coli along with pDP3615.
- ⁇ -galactosidase ⁇ -gal
- a plasmid containing the gene encoding ⁇ -gal was transformed into E. coli along with plasmid pDP3615. Expression of both OVA and ⁇ -gal in these strains is under the control of IPTG-inducible phage T7 RNA polymerase.
- OVA protein could be detected throughout the entire cytosolic compartment within 30 minutes of bacterial uptake. Moreover, at least 50% of macrophages that had phagocytosed a single bacterium demonstrated release of OVA into the cytosol within 30 minutes following bacterial uptake. In some instances, OVA protein could be detected leaking from phagosomes into the cytosol as early as 10 minutes post-phagocytosis of bacteria.
- ⁇ -gal is a 116 kD protein that functions as a 465 kD tetramer (33). Whether ⁇ -gal is associated as a tetramer prior to release into the cytosol is unknown, but these data indicate that at a minimum a 116 kD protein can be delivered to the cytosol of macrophages using the E. coli /LLO delivery system and still retain its enzymatic activity.
- CTLs cytotoxic T-lymphocytes
- APC antigen presenting cell
- proteases process the antigen to peptide epitopes which are subsequently presented on the surface of the APC in association with major histocompatibility (MHC) class I molecules for recognition by CD8 + CTLs (37-39).
- MHC major histocompatibility
- E. coli expressing LLO and an antigenic protein were added to macrophages and the processing and presentation of a peptide epitope derived from OVA was accessed using the B3Z T-cell hybrid.
- B3Z is a LacZ-inducible CD8 + T-cell hybrid specific for OVA residues 257-264 (SIINFEKL, SEQ ID NO:6) presented on the murine K b MHC class I molecule (27, 28).
- the presentation of the SIINFEKL epitope (SL8) to B3Z cells results in the induction of ⁇ -gal synthesis by B3Z.
- the amount of ⁇ -gal produced can be measured by the hydrolysis of the chromogenic substrate CPRG and is an indication of the amount of SL8/K b complexes presented on the surface of APCs (27, 30).
- Bacteria were added to macrophages and phagocytosis allowed to proceed for one hour, followed by the removal of extracellular bacteria and addition of B3Z T-cells.
- processing and presentation of SL8/Kb to B3Z T-cells occurred when E. coli expressing both LLO and OVA were added to macrophages.
- the indicated number of E E.
- coli strain DP-E3617 expressing LLO and OVA were added to 1 ⁇ 10 5 IC-21 macrophages in each well of a 96-well plate. Processing and presentation of SL8/K b was assayed as described in FIG. 1. Immediately prior to the addition of bacteria, APCs were either left untreated (Not Fixed) or fixed (Pre-Fixed) with 1% paraformaldehyde as described (31). Fixing APCs prior to the addition of bacteria completely abrogated the ability of macrophages to process and present SL8/K b complex to B3Z T-cells, as evident by an equivalent response as that seen when no bacteria were added to the macrophages (FIG. 1).
- FIG. 2B the time requirement for processing and presentation of SL8/K b complex was addressed.
- 1 ⁇ 10 6 E. coli strain DP-E3617 expressing LLO and OVA were added to 1 ⁇ 10 5 IC-21 APCs in each well of a 96-well plate.
- extracellular bacteria were removed by washing with PBS and APCs were either immediately fixed with 1% paraformaldehyde (1 hour) or incubated further in media containing 100 ⁇ g/ml gentamicin.
- APCs were fixed with 1% paraformaldehyde until all time points were completed.
- APCs were washed with PBS and 1 ⁇ 10 5 B3Z T cells added to each well. Presentation of SL8/K b was assayed as described above. Labels indicate the time elapsed post addition of bacteria prior to fixation of APCs. Dark shaded bars indicate samples to which E. coli strain DP-E3617 were added. Light shaded bar indicates samples to which no bacteria but 90 nM synthetic SL8 was added with B3Z cells. The (Not Fixed) samples received no fixation prior to the addition of B3Z cells. Data presented is from triplicate groups of wells from one of three experiments with identical results.
- E. coli expressing cytoplasmic LLO can be used to deliver a co-expressed protein to the cytosol of macrophages.
- the delivery of protein to macrophages was rapid and efficient with protein first appearing in the cytosol within ten minutes following bacterial uptake.
- large enzymatically active proteins can be introduced into the cytosol using this method as demonstrated by the delivery of active ⁇ -gal.
- the mechanism of delivery may be as follows. Subsequent or concomitant to phagocytosis, the E. coli are killed and degraded within phagosomes causing the release of LLO and the target protein from the bacteria. LLO acts by forming large pores in the phagosomal membrane thus releasing the target protein into the cytosol. In any event, any protein that can be synthesized in E. coli can be delivered to the macrophage cytosol.
- LLO is an essential determinant of pathogenesis whose role is to mediate release of L. monocytogenes from a phagosome.
- the biological properties of LLO make it well suited for use in our system.
- LLO has an acidic pH optimum which facilitates its action in a phagosome (40, 41).
- LLO released by degraded E. coli would retain its biological activity.
- the data presented here demonstrate that the amount of LLO expressed was sufficient to allow the rapid release of protein into the cytosol. Based on SDS-PAGE analysis of known quantities of purified LLO protein, we estimate approximately 1 ⁇ 10 5 molecules of LLO per E. coli cell.
- LLO LLO-like pore-forming cytolysin
- a second property of LLO is its relative lack of toxicity thought to be due to its proteolysis in the cytosol of host cells (43). Indeed, secretion by L. monocytogenes of a related pore-forming hemolysin, perfringolysin O, resulted in death of the infected cells (44).
- E. coli /LLO delivery system There are a number of advantages and applications of the E. coli /LLO delivery system. Many methodologies for delivering protein to the cytosol of macrophages require the prior purification of the protein to be delivered. With the E. coli /LLO mediated delivery of protein, no protein purification is required, only expression of the target protein in E. coli is necessary. Furthermore, with many alternative methods, delivery is restricted to minute amounts of protein or a limited number of cells and the in vivo delivery of protein can not be achieved (2). Using the E. coli /LLO system, high levels of protein can be delivered to the cytosol of virtually all of the cells in culture.
- the level of protein produced and ultimately delivered to the cytosol of macrophages can be controlled.
- This system can be used in vivo and by expressing invasive determinants from other bacterial species, the E. coli may be modified to enter cells other than macrophages.
- this system has applications for the delivery of pathogen-specific protein antigens or DNA.
- the results of this example show that the E. coli /LLO system is particularly effective for the introduction of protein into the MHC class I pathway of antigen processing and presentation.
- efficient processing and surface presentation of peptide/MHC complexes occurred rapidly, within 1-2 hours following addition of bacteria to macrophages (FIG. 2B). Delivery to the MHC class I pathway was enhanced greater than 4-logs compared to E. coli expressing OVA alone.
- the efficiency of antigen delivery provides for the E. coli /LLO system to be used for the induction of CTLs in vivo.
- the efficient in vivo delivery of antigens to generate a protective immune response is a significant challenge in vaccine development.
- the use of bacterial vectors that have evolved to invade and replicate in mammalian cells such as Shigella (11, 12), Salmonella (8-10), and Listeria monocytogenes (52-55) are being explored as methods for the delivery of both protein antigens and DNA. Although these vehicles have had success in eliciting protective immune responses, the in vivo use of pathogenic bacteria has inherent risks.
- One strategy to overcome these obstacles has been to engineer attenuated E.
- DAP diaminopimelate
- pWR100 plasmid pWR100 from Shigella flexneri
- S. flexneri yet following brief replication, spontaneously lyse in the cytosol and allow for the delivery of DNA for subsequent expression in the host cell.
Abstract
The invention provides methods and compositions relating to intracellular delivering of agents to eukaryotic cells. The compositions include microbial delivery vehicles such as nonvirulent bacteria comprising a first gene encoding a nonsecreted foreign cytolysin operably linked to a heterologous promoter and a second gene encoding a different foreign agent. The foreign agent may be a nucleic acid or protein, and is frequently bioactive in and therapeutic to the target eukaryote. In addition, the invention provides eukaryotic cells comprising the subject nonvirulent bacteria and nonhuman eukaryotic host organisms comprising such cells.
Description
- This application is a continuation of and claims priority under 35 U.S.C.§ 120, of U.S. Ser. No. 09/949,109, filed Sep. 7, 2001, now U.S. Pat. No. 6,599,502, which is a continuation of Ser. No. 09/469,197, filed Dec. 21, 1999, now U.S. Pat. No. 6,287,556, which is a continuation of U.S. Ser. No. 09/133,914, filed Aug. 13, 1998, now U.S. Pat. No. 6,004,815, which are incorporated herein by reference.
- [0002] The disclosed inventions were made with Government support under Grant (Contract) Nos. A127655-10 BD37 awarded by the National Institutes of Health. The government may have rights in these inventions.
- 1. Field of the Invention
- The field of this invention is microbial-based intracellular delivery of agents to eukaryotic cells.
- 2. Background
- The efficient delivery of macromolecules to the cytosol of mammalian cells is of fundamental importance in such processes as the generation of transfected phenotypes and the study of protein function and localization. Furthermore, delivery of macromolecules to the cytosol is also important for the induction of cell-mediated immunity and is a significant challenge facing the rational design of vaccines to intracellular pathogens. Numerous methodologies currently exist for delivering macromolecules to mammalian cells. These include but are not limited to: mechanical techniques such as electroporation (1) and microinjection (2); fusion methodologies such as fusion with vesicles and liposomes (2); chemical treatments employing the use of ATP or EDTA (3) or the external addition of molecules mixed with pore-forming toxins such as α-toxin ofStaphylococcus aureus (4). Many of these methods have a disadvantage in that the molecule to be delivered may require laborious purification (i.e. protein) or the delivery method is limited to use in vitro. In order to overcome these obstacles, investigators have sought to use biological vectors that can enter tissues, cells and specific cellular compartments for the delivery of macromolecules. These vectors are often derived from either retroviruses or bacteria that have evolved to invade and replicate in specific hosts, organs, or cell types. While retroviral vectors have been used for the delivery and subsequent expression of DNA in host cells (5-7), bacterial vectors have been exploited primarily for the delivery of antigenic proteins and more recently adapted for the delivery of DNA to mammalian cells (8-12).
- Relevant Literature
- Lee et al. (1997) U.S. Pat. No. 5,643,599 and Lee et al. (1996)J. Biol. Chem. 271, 7249-7252 describe hemolysin loaded liposomes for intracellular delivery of macromolecules. Dietrich, G., et al. (1998) Nature Biotech. 16, 138-139 and Ikonomidis, G., et al. (1997) Vaccine 15, 433-440 describe the use of Listeria monocytogenes as a macrophage delivery vehicle. Sizemore, D. R., Branstrom, A. A., & Sadoff, J. C. (1995) Science 270, 299-302 and Courvalin, P., et al. (1995) C. R. Acad. Sci. III 318, 1207-1212 describe the use of attenuated Shigella and invasive strains of Shigella flexneri and E. coli, respectively, as a DNA delivery vehicle. Hess, J., et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 5299-5304; and Darji, A., et al. (1995) J. Biotechnol. 43, 205-212 describe the expression of listeriolysin in several heterologous systems: an invasive E. coli, Mycobacterium bovis and Listeria innocua, respectively. Moriishi et al. (1996) FEMS Immunol. Med. Microbiol. 16, 213-222, 217 describe the transformation of an E. coli with a plasmid encoding listeriolysin. Sanderson, S., Campbell, D. J., & Shastri, N. (1995) J. Exp. Med. 182, 1751-1757, describe the cloning of a Listeria monocytogenes genomic library in E. coli. Higgins and Portnoy (1998) Nature Biotech. 16, 181-185 review bacterial delivery of DNA.
- The invention provides methods and compositions relating to intracellular delivering of agents to eukaryotic cells. The compositions include microbial delivery vehicles such as nonvirulent bacteria comprising a first gene encoding a nonsecreted foreign cytolysin operably linked to a heterologous promoter and a second gene encoding a different foreign agent. In particular embodiments, the bacteria may be variously invasive to the target cell, autolysing within target cell endosomes and preferably, a laboratory strain ofE. coli. The cytolysin may lack a functional signal sequence, and is preferably a listeriolysin. The foreign agent may be a nucleic acid or protein, and is frequently bioactive in and therapeutic to the target eukaryote. In addition, the invention provides eukaryotic cells comprising the subject nonvirulent bacteria and nonhuman eukaryotic host organisms comprising such cells. The invention also provides methods for introducing foreign agents into eukaryotic cells comprising the step of contacting the cell in vivo or in vitro with the subject bacteria under conditions whereby the agent enters the cell. In particular embodiments, the bacterium is endocytosed into a vacuole of the cell, undergoes lysis and the cytolysin mediates transfer of the agent from the vacuole to the cytosol of the cell.
- FIG. 1. Presentation of SL8/Kb complex to B3Z T-cells.
- FIGS. 2A and 2B. Time requirement for presentation of SL8/Kb complex.
- The following preferred embodiments and examples are offered by way of illustration and not by way of limitation.
- The subject bacteria comprise a first gene encoding a nonsecreted foreign cytolysin operably linked to a heterologous promoter. A wide variety of foreign (i.e. not native to the microbial delivery vehicle) cytolysins may be used so long as the cytolysin is not significantly secreted by the microbe and facilitates cytosolic delivery of the foreign agent as determined by the assays described below. Exemplary cytolysins include phospholipases (see, e.g., Camilli, A., et at.,J. Exp. Med. 173:751-754 (1991)), pore-forming toxins (e.g., an alpha-toxin), natural cytolysins of gram-positive bacteria, such as listeriolysin O (LLO, e.g. Mengaud, J., et al., Infect. Immun. 56:766-772 (1988) and Portnoy, et al., Infect. Immun. 60:2710-2717 (1992)), streptolysin O (SLO, e.g. Palmer M, et al., 1998, Biochemistry 37(8):2378-2383) and perfringolysin 0 (PFO, e.g. Rossjohn J, et al., Cell 89(5):685-692). Where the target cell is phagosomal, acid activated cytolysins may be advantageously used. For example, listeriolysin O exhibits greater pore-forming ability at mildly acidic pH (the pH conditions within the phagosome), thereby facilitating delivery of the liposome contents to the cytoplasm (see, e.g., Portnoy, et al., Infect. Immun. 60:2710-2717 (1992)). Furthermore, natural cytolysins are readily modified to generate mutants which are screened in the assays described below or otherwise known in the art (e.g. Awad M M, et al., Microb Pathog. 1997, 22(5): 275-284) desired activity modifications. In general, the screening assays measure the ability of a candidate cytolysin to confer on a bacterium the ability to render a target cell vacuole permeable to a label (e.g., a fluorescent or radioactive label) that is contained in the vacuole. In a particular example, the invention provides mutations in natural cytolysin wherein highly conserved cysteine residues (e.g., cysteine 460 in PFO, cysteine 486 in LLO) are replaced by conservative amino acid substitutions which are not subject to reduction in order to prepare oxidation/reduction-insensitive cytolysin mutants which exhibit improved lytic activity. Alternatively, mutant cytolysins are selected from naturally occurring mutants by, for example, identifying bacteria which contain cytolysins that are capable of lysing cells over a narrow pH range, preferably the pH range which occurs in phagosomes (pH 5.0-6.0), or under other conditions (e.g., ionic strength) which occur in the targeted phagosomes. Nonsecreted cytolysins may be provided by various mechanisms, e.g. absence of a functional signal sequence, a secretion incompetent microbe, such as microbes having genetic lesions (e.g. a functional signal sequence mutation), or poisoned microbes, etc.
- The bacteria also comprise a second gene encoding a foreign agent different from the cytolysin, and the subject methods may be used to deliver a wide variety of such foreign agents for a variety of applications, including diagnosis, therapy including prophylactics such as immunizations (see, e.g. HIV vaccine, Table 1) and treatments such as gene therapy (especially of single gene disorders amenable to localized treatment, see Table 1, below), biosynthesis, etc.; essentially any agent that the microbial host can be engineered to produce. In a particular embodiment, the agent is largely retained by the microbe until lysis within the target cell vacuole. Note that the first and second genes may be the same, i.e. the same nucleic acid encodes both the cytolysin and the foreign agent. For example, in a particular embodiment, the foreign agent is expressed in frame with the cytolysin as a fusion protein. In other embodiments, the microbes are engineered to deliver libraries of agents for screening, e.g. Tenson T, et al.,J Biol Chem 1997 Jul. 11;272(28):17425-17430.
- A wide variety of nucleic acid-based agents may be delivered, including expression vectors, probes, primers, antisense nucleic acids, knockout/in vectors, ribozymes, etc. For example, the subject bacteria are used to deliver nucleic acids which provide templates for transcription or translation or provide modulators of transcription and/or translation by hybridizing to selected endogenous templates, see, e.g. U.S. Pat. No. 5,399,346 for a non-limiting list of genes that can be administered using gene therapy and diseases that can be treated by gene therapy. For example, polynucleotide agents may provide a coding region operably linked to a transcriptional regulatory region functional in a target mammalian cell, e.g. a human cytomegalovirus (CMV) promoter. In particular, the polynucleotide may encode a transcription factor, whereby expression of the transcription factor in the target cell provides activation or de-activation of targeted gene expression in the target cell. In another example, RNA virus infected cells are targeted by microbes delivering viral RNA-specific ribozymes, e.g. HIV-infected T-cells, leukemia virus infected leukocytes, hepatitis C infected liver cells. In yet another embodiment, labeled probes are delivered which effect in situ hybridization-based diagnostics.
- A wide variety of polypeptide-based agents may also be delivered, including antibiotics, insecticides, fungicides, anti-viral agents, anti-protozoan agents, enzymes, anti-cancer agents (e.g. cyclin dependent kinase (CDK) inhibitors such as P16, P21 or P27), antibodies, anti-inflammatory peptides, transcription factors, antigenic peptides, etc. Exemplary therapeutically active polypeptides which can be delivered by the subject invention are described in Nature Biotech 16(2), entire issue, etc. In a particular embodiment, the invention provides for the delivery to antigen-presenting cells of antigenic polypeptides which are presented in association with MHC proteins. In another particular embodiment, both nucleic acids and proteins are delivered together contemporaneously, in the same administration or in the same microbe. In some such applications, the nucleic acids and proteins can act in concert, e.g. an integrating vector and an integrase, and RNA and a reverse transcriptase, a transposon and a transposase, etc.
- The subject methods may also be used to deliver a wide variety of other foreign agents that are synthesized by the host microbe. For example, microbes may be selected for, or engineered to contain, biosynthetic machinery to produce any microbiologically producible agent compatible with the subject methods (e.g. sufficiently microbe impermeant to provide effective delivery to the target cell). Preferred such agents are those that are contraindicated for convenient direct (e.g. oral) administration, because of, for example, gut inactivation, toxicity, intolerance, impermeability, etc. In fact, even agents providing significant toxicity to the microbial host find use so long as an effective amount of the agent may be loaded (by synthesis) or maintained in the microbe (see, e.g. LLO toxicity, below).
- A wide variety of nonvirulent, non-pathogenic bacteria may be used; preferred microbes are relatively well characterized strains, particularly laboratory strains ofE. coli, such as MC4100, MC1061, DH5α, etc. Other bacteria that can be engineered for the invention include well-characterized, nonvirulent, non-pathogenic strains of Listeria monocytogenes, Shigella flexneri, mycobacterium, Salmonella, Bacillus subtilis, etc. In a particular embodiment, the bacteria are attenuated to be nonreplicative, nonintegrative into the host cell genome, and/or non-motile inter- or intra-cellularly. A wide variety of suitable means for microbial attenuation are known in the art. In another particular embodiment, the bacteria are dead or non-viable prior to endocytosis by the target cell or administration to the target organism, obviating any microbial growth or metabolism in the target cell. A wide variety of suitable means for killing or rendering the bacteria nonviable are known in the art, including fixation with organic solvents such as methanol, UV irradiation, heat, freeze-drying, etc. Preferred methods preserve the ability of the microbial membrane and/or wall to retain the cytolysin and the foreign agent. In this embodiment, the first and second genes are sufficiently expressed to load the microbe with an effective amount of the cytolysin and foreign agent prior to microbial cell death. Generally the bacteria contain (i.e. are loaded by expression within the bacteria with) with from about ten to one thousand, preferably from about one hundred to one thousand cytolysin molecules per bacterium.
- The microbes of the invention can be used to deliver the foreign agent to virtually any target cell capable of endocytosis of the subject microbe, including phagocytic, non-phagocytic, pathogenic or diseased cells. Exemplary target animal cells include epithelial cells, endothelial cells, muscle cells, liver cells, pancreatic cells, neural cells, fibroblasts, tumor cells, leukocytes such as macrophages, neutrophils, B-cells, T-cells, monocytes, etc., etc. The subject methods generally require microbial uptake by the target cell and subsequent lysis within the target cell vacuole (including phagosomes and endosomes). While phagocytic target cells generally provide for microbial uptake and lysis, for many cell types, it is necessary to provide the bacteria with an invasin to facilitate or mediate uptake by the target cell and an autolysin to facilitate or mediate autolysis of the bacteria within the target cell vacuole. A wide variety of suitable invasins and autolysins are known in the art. For example, both Sizemore et al. (Science, 1995, 270:299-302) and Courvalin et al. (C.R. Acad. Sci. Paris, 1995, 318:1207-12) teach expression of an invasin to effect endocytosis of the bacterium by a target cell and suitable microbial autolysins are described by Cao et al., Infect Immun 1998, 66(6): 2984-2986; Margot et al., J. Bacteriol 1998, 180(3):749-752; Buist et al., Appl Environ Microbiol, 1997, 63(7):2722-2728; Yamanaka et al., FEMS Microbiol Lett, 1997, 150(2): 269-275; Romero et al., FEMS Microbiol Lett, 1993, 108(1):87-92; Betzner and Keck, Mol Gen Genet, 1989, 219(3): 489-491; Lubitz et al., J. Bacteriol, 1984, 159(1):385-387; and Tomasz et al., J. Bacteriol, 1988, 170(12): 5931-5934. Providing the advantage of delayed lysis are temperature-sensitive autolysins, time-sensitive autolysins (see, e.g. Chang et al., 1995, J Bact 177, 3283-3294; Raab et al., 1985, J Mol Biol 19, 95-105; Gerds et al., 1995, Mol Microbiol 17, 205-210) and addiction (poison/antidote) autolysins, (see e.g. Magnuson R, et al., 1996, J Biol Chem. 271(31), 18705-18710; Smith A S, et al., 1997, Mol Microbiol. 26(5), 961-970).
- Administration of the microbe to target cells may be in vitro or in vivo according to conventional methodologies. In either case, the methods generally involve growing the microbes, inducing the expression of the first and second genes, and contacting the target cells with an effective amount of bacteria sufficient to effect the desired activity of the foreign agent in the target cell. Immunofluorescense may be used to image and track the contents of the bacteria upon administration to the cells in vivo or in vitro.
- In vitro or ex vivo administration generally involves contacting the target cell with an effective amount of the microbes of the invention. Exemplary in vitro administrations are described and/or cited by reference below. In vitro applications include protein delivery (e.g. for functional determinations, toxin delivery to targeted cells in culture, half-life, degradation and localization determinations), nucleic acid delivery (e.g. DNA to transfected cell lines, genomic libraries to screen and identify specific antigens, i.e. expression cloning, etc.)
- In vivo administration generally involves administering a pharmaceutical composition containing a therapeutically effective amount of the microbes of the invention. Generally, the therapeutically effective amount is between about 1 μg and 100 mg/kg, preferably between about 1 μg and 1 mg/kg. The microbes are formulated into a pharmaceutical composition by combination with an appropriate pharmaceutically acceptable excipient in accordance with routine procedures known to one of ordinary skill in the art. The microbes may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds. The microbes may be formulated into preparations in solid, semisolid, or liquid form such as tablets, capsules, powders, granules, ointments, solutions, suppositories, and injections, in usual ways for topical, nasal, oral, parenteral, or surgical administration. Administration in vivo can be oral, mucosal, nasal, bronchial, parenteral, subcutaneous, intravenous, intra-arterial, intra-muscular, intra-organ, intra-tumoral, surgical or in general by any means typical of a gene therapy administration. Administration will be selected as is appropriate for the targeted host cells. Target cells may also be removed from the subject, treated ex vivo, and the cells then replaced into the subject. Exemplary methods for in vivo administration are described in Shen et al., Proc Natl Acad Sci USA 1995, 92(9):3987-3991; Jensen et al, Immunol Rev 1997, 158: 147-157; Szalay et al., Proc Natl Acad Sci USA 1995, 92(26):12389-12392; Belyi et al, FEMS Immunol Med Microbiol 1996, 13(3): 211-213; Frankel et al., J. Immunol 1995, 155(10):4775-4782; Goossens et al., Int Immunol 1995, 7(5):797-805; Schafer et al., J. Immunol 1992, 149(1):53-59; and Linde et al., Vaccine 1991, 9(2):101-105.
- The foregoing methods and compositions are demonstrated to be effective in a wide variety of exemplary applications. In one application, a K12 strain ofE. coli is engineered with a signal sequence deficient LLO gene operably linked to the constitutive tet promoter for expressing the cytolysin in the bacterium and a second gene encoding a truncated BRCA1 cancer antigen, under regulatory control of a trc or tac promoter. The cytolysin and cancer antigen are expressed to maximum levels, the bacteria are then fixed with methanol, and the killed bacteria loaded with the cytolysin and cancer antigen are then injected into solid breast tumors in three weekly injections. At four weeks, a cancer antigen-specific cytotoxic T-cell response (CTL response) and tumor size reduction is detected. As shown in Table 1, analogous studies conducted in a variety of animals and animal cell types, both in vivo and in vitro, using a variety of agents, secretory deficient cytolysins, bacterial types and methods demonstrate consistent delivery of the agent to the target cell cytosol, as measured by agent activity, immunoassay, or other delivery monitoring assays described herein.
TABLE 1 Microbial-Based Delivery Cytosol Target Cell Indication Agent Lysin Bacteria Administration Delivery transformed human acites tumor human tumor LLO E. coli, intraperitoneal +++ macrophage in nude mice antigen hTA1 JM109 injection (DE3) rat liver hepatocellular p51 tumor LLOM1 E. coli, in situ; intratumor +++ carcinoma suppressor DP-E3619, injection invasin/autolysin rat kidney genetic angiotensin LLOM2 S. typhimurium, ex vivo +++ nephopathy converting attenuated, enzyme invasin/autolysin mouse brain neurodegeneration cFos gene LLOM3 S. typhimurium, in situ; intracranial +++ expression attenuated, implant construct invasin/autolysin mouse pancreas transformation γ-interferon LLOM4 E. coli, in vitro +++ expression JM109 (DE3) construct pig muscle muscular insulin-like PLO E. coli, in situ; i.m. +++ atrophy growth factor I DP-E3618, injection (IGF-I) invasin/autolysin human breast transformation anti- SLO E. coli, in vitro +++ estrogen receptor DP-E3617, antibody invasin/autolysin expression construct human prostate localized ribozyme or LLO S. typhimurium, in situ; intratumor +++ prostatic antisense attenuated injection carcinoma against CDK invasin/autolysin 2 or CDK4 human lymphoid lymphoma tumor LLO E. coli, ex vivo +++ necrosis factor DP-E3616 (TNF) human bone marrow mylomoid Hepatocyte SLO E. coli, ex vivo +++ leukemia growth DP-E3615 factor/scatter factor (HGF/SF) human lymphoid HIV infection HIV RT LLO S. typhimurium, ex vivo +++ gene-specific attenuated ribozyme human hepatic cells Hepatitis C Hepatitis C LLO S. typhimurium, in vivo; direct +++ infection virus-specific attenuated, injection ribozyme invasin/autolysin human hepatic cells diabetes insulin LLO S. typhimurium, in vivo; direct +++ receptor attenuated, injection expression invasin/autolysin construct human beta islet cells diabetes insulin LLO S. typhimurium, in vivo; direct +++ expression attenuated, injection construct invasin/autolysin murine fibroblast fibroblastoma diptheria toxin LLO S. typhimurium, in vivo; direct +++ attenuated, injection invasin/autolysin feline retinal cells retinal cGMP LLO E. coli, intraocular +++ degenerative phospho- JM109 (DE3), injection disease diesterase-beta invasin/autolysin human cytotoxic T-cells melanoma melanosomal LLO E. coli, in vivo; IV +++ proteins JM109 (DE3) injection human epithelium Herpes infection antisense LLO S. typhimurium, in vivo; oral, opical +++ RNAseP attenuated, abrasion construct invasin/autolysin murine macrophages IL-2 production NFAT LLO S. typhimurium in vitro +++ - I. Delivery of Protein to the Cytosol of Macrophages UsingEscherichia coli K-12 Expressing Listeriolysin O
-
- Bacterial Strains and Plasmids. All bacterial strains and plasmids used in this report are listed in Table 2.
TABLE 2 E. coli strains and plasmids used in this work Strain or Plasmid Description Reference or source pACYC184 cloning vector; Tcr Cmr (23) pET28a over-expression vector; Kanr (Novagen, Inc.) pET29b over-expression vector; Kanr (Novagen, Inc.) pTL61T lacZ transcriptional fusion vector; Apr (24) pBluescript SK- cloning vector; Apr (Stratagene, Inc.) pTrcHisC/Ova pTrcHisC::ova (D. Campbell, UCB) pDP3615 pACYC184 tet::hly Herein pDP3616 pET28a pT7::ova Herein pDH70 pBluescript SK- pT7::lacZ Herein MC4100(DE3) F araD139 Δ(argF-lac)U169 rpsL150 (Schifferli, U. Penn) (Strr)relA1 flbB5301 deoC1 ptsF25 rbsR with DE3, a λ prophage carrying the T7 RNA polymerase gene JM109(DE3) endA1 recA1 gyrA96 thi hsdR17 relA1 supE44 (Promega, Co.) Δ(lac-proAB) [F′ traD36 proAB lacIqZΔM15] DE3 DP-E3615 MC4100(DE3) harboring pDP3615 Herein DP-E3616 MC4100(DE3) harboring pDP3616 Herein DP-E3617 MC4100(DE3) harboring pDP3615 and pDP3616 Herein DP-E3618 JM109(DE3) harboring pDH70 Herein DP-E3619 JM109(DE3) harboring pDP3615 and pDH70 Herein - Plasmid pDP3615 was generated by PCR amplification of the hly gene encoding LLO lacking its secretion signal sequence (22). DNA sequences encoding mature LLO were first PCR amplified and cloned into pET29b (Novagen, Inc., Madison, Wis.) using oligonucleotide primer 5′-GGAATTCCATATGAAGGATGCATCTGCATTCAAT-3′ (SEQ ID NO:1) generating a NdeI restriction site at the 5′-end of the gene fragment and primer 5′-CGGGATCCTTATTATTCGATTGGATTATCTACT-3′ (SEQ ID NO:2) generating a BamHI restriction site at the 3′ end of the gene fragment. Following ligation into the pET29b vector, the DNA sequences encoding mature LLO along with the upstream translation initiation site found in pET29b were amplified using primer 5′-CGCGATATCCTCTAGAAATAATTTTG-3′ (SEQ ID NO:3) generating an EcoRI restriction site at the 5′ end of the gene fragment and the same primer used previously to generate a BamHI restriction site at the 3′ end of the gene fragment. The amplified fragment was ligated into pACYC184 (23) placing transcription of the mature hly gene under control of the tet gene promoter. Plasmid pDP3616 was generated by subcloning a NcoI-HindIII fragment containing DNA sequences encoding truncated OVA from plasmid pTrcHisC/OVA. The DNA fragment was ligated into the over-expression vector pET28a (Novagen, Inc., Madison, Wis.). Plasmid pDH70 was generated by PCR amplification of the promoterless lacZ gene in plasmid pTL61T (24) using oligonucleotide primers 5′-AGGCGTCGACGGTTAATACGACCGGGATCGAG-3′ (SEQ ID NO:4) and 5′-AGGCGTCGACAGGCCTTACGCGAAATACGGGCAGACATGG-3′ (SEQ ID NO: 5) generating SalI restriction sites at both the 5′ and 3′ ends of the fragment. The amplified fragment was ligated into pBluescript SK− (Stratagene, Inc., La Jolla, Calif.) placing transcription of the lacZ gene under control of a phage T7 promoter. Plasmid DNA was transferred toE. coli strains by transformation, using standard methods (25). E. coli strains were grown in Luria-Bertani (LB) medium. The strains were stored at −70° C. in LB medium plus 40% glycerol. Antibiotics were used at the following concentrations: ampicillin, 100 μg/ml; chloramphenicol, 40 μg/ml; and kanamycin, 30 μg/ml.
- Expression of Target Proteins.E. coli strains were inoculated from a LB agar plate into 2 mls of LB medium and grown overnight to stationary phase at 37° C. with aeration. Cultures were diluted 1:100 in 10 mls of LB medium in 250 ml flasks and grown 2 hours with aeration at 30° C. Target protein expression was induced by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to 1 mM and growth continued until cultures reached an OD600 of 0.5. Equivalent numbers of bacteria were centrifuged (14,000×g) for 1 minute and washed once with phosphate buffered saline (PBS). Washed samples were suspended in Final Sample Buffer (0.0625M Tris pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue) boiled for 5 minutes and total cellular protein analyzed by polyacrylamide gel electrophoresis followed by staining with Coomassie Brilliant Blue.
- Determination of Hemolytic Activity. Following bacterial growth and induction of target proteins, 1 ml aliquots of bacteria were centrifuged (14,000×g) for 1 minute and washed once with PBS. Samples were resuspended in 1 ml of PBS and lysed by sonication. Soluble extract fractions were obtained by centrifuging lysed samples for 10 minutes (14,000×g) at 4° C. and saving the supernatant. Hemolytic activity in the soluble fractions was determined as previously described (26) and is expressed as the reciprocal of the dilution of extracts required to lyse 50% of sheep erythrocytes.
- Cell Culture. Cell lines were maintained in RPMI 1640 medium or DMEM supplemented with 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, Utah), 2 mM glutamine, 1 mM pyruvate, 50 μM 2-mercaptoethanol, penicillin (200 units/ml), and streptomycin (200 μg/ml) at 37° C. in a 5% CO2/air atmosphere. The IC-21 and Raw 309 Cr.1 mouse macrophage cell lines were obtained from the American Type Culture Collection (ATCC, Rockford, Md.). The B3Z T-cell hybrid is a LacZ-inducible CD8+ T-cell hybridoma specific for OVA residues 257-264, SIINFEKL (SL8)(SEQ ID NO:6), presented on the murine Kb MHC class I molecule (27, 28).
- Delivery of Protein to the Cytosol of Macrophages. IC-21 cells were seeded onto 18 mm glass coverslips in 35 mm dishes in RPMI medium without antibiotics. One hour prior to addition of bacteria, dishes were placed at 4° C. Medium was removed from the dishes andE. coli were added in cold RPMT medium without antibiotics to obtain an infection ratio of one bacterium/macrophage. Samples were incubated at 4° C. for one hour to allow association of bacteria and macrophages. Samples were washed five times with 3 mls of cold PBS and 37° C. RPMI medium added. Samples were incubated at 37° C. in a 5% CO2/air atmosphere for up to one hour. At varying intervals during incubation of macrophages and E. coli, coverslips were removed and fixed for subsequent detection of protein.
- Detection of Target Protein in Macrophages. Following delivery of β-gal to macrophages, coverslips were fixed in cold 2% formaldehyde/0.2% glutaraldehyde for 5 minutes at 4° C. β-gal activity was detected by staining with 5-bromo-4-chloro-3-indolyl β-galactopyranoside (X-gal, Sigma Immunochemicals, St. Louis, Mo.) as previously described (27). For detection of OVA, coverslips were fixed in 3.2% electron microscopy grade paraformaldehyde (Electron Microscopy Sciences, Ft. Washington, Pa.) overnight at 4° C. in aluminum foil wrapped containers. OVA was detected by immunofluorescence as previously described (29) with the exception that polyclonal rabbit anti-OVA antibody (Calbiochem, San Diego, Calif.) and LRSC-conjugated donkey anti-rabbit IgG antibody (Jackson ImmunoResearch, West Grove, Pa.) were used for detection.
- Antigen Presentation Assays. Presentation of SL8/Kb complex to B3Z cells was determined as previously described (30). Briefly, E. coli were added to 1×105 antigen presenting cells (APCs) in each well of a 96-well microtiter plate. Following one hour of incubation at 37° C. in a 5% CO2/air atmosphere, extracellular bacteria were removed by washing three times with PBS and 1×105 B3Z T cells were added to each well in medium containing 100 μg/ml gentamicin. Following 15 hours of incubation at 37° C. in a 5% CO2/air atmosphere, cultures were washed once with PBS and lysed by addition of 100 μl PBS buffer containing 100 μM 2-mercaptoethanol, 9 mM MgCl2, 0.125% NP40, and 0.15 mM chlorophenolred-β-galactoside (CPRG, Calbiochem, San Diego, Calif.). After 4-6 hours at 37° C., 50 μl of stop buffer (300 mM glycine and 15 mM EDTA in water) was added and the absorbance at 570 nm of each well was determined using a 96-well plate reader. Where appropriate, APCs were fixed with 1% paraformaldehyde prior to the addition of B3Z cells as described (31). Synthetic SL8 peptide was obtained from Research Genetics, Inc. (Huntsville, Ala.) and was incubated with APCs and B3Z cells at a saturating concentration of 90 nM in RPMI medium.
- Expression of Listeriolysin O and Target Proteins. To facilitate expression of mature cytoplasmic LLO inE. coli, the hly gene encoding LLO lacking its N-terminal signal sequence (22) was cloned into the plasmid vector pACYC184 to generate pDP3615 as described in Materials and Methods. Transcription of the truncated hly gene in pDP3615 is under the control of the constitutive tet gene promoter. Proteins to be delivered to the cytosol of macrophages were expressed from co-resident plasmids in E. coli. We chose chicken ovalbumin (OVA) as one of the representative proteins to deliver to the cytosol of macrophages. OVA is not toxic to E. coli and can be readily expressed to high levels (32). A plasmid encoding truncated (32 kD) OVA was transformed into E. coli along with pDP3615. In order to determine if a large protein with a measurable enzymatic activity could be delivered to the cytosol of macrophages, we expressed β-galactosidase (β-gal) along with LLO in E. coli. A plasmid containing the gene encoding β-gal, was transformed into E. coli along with plasmid pDP3615. Expression of both OVA and β-gal in these strains is under the control of IPTG-inducible phage T7 RNA polymerase. We next analyzed the hemolytic activity and protein expression profiles of these strains. Following IPTG induction, OVA and β-gal were expressed to approximately 20% of the total E. coli cellular protein as determined by SDS-PAGE. To verify expression of active LLO protein within E. coli, hemolytic activity contained in the soluble fraction of E. coli extracts was determined as described above. All of the strains expressing LLO contained approximately 500-600 hemolytic units of activity in the soluble extracts. No measurable hemolytic activity was found in the culture medium in which the E. coli were grown. These data indicate that functional LLO protein was contained within the E. coli cells and not secreted to the extracellular environment.
- Delivery of Protein to the Cytosol of Macrophages. To examine the ability ofE. coli expressing LLO to deliver a co-expressed target protein to the cytosol of macrophages, E. coli expressing LLO and OVA were added to macrophages to obtain an infection ratio of approximately one bacterium/macrophage. The presence of OVA either in phagosomes or in the cytosol was determined by immunofluorescence microscopy. When bacteria expressing OVA in the absence of LLO were added to macrophages, protein was contained within phagosomes and no OVA could be detected in the cytosol of macrophages within one hour following phagocytosis. In contrast, when bacteria expressing both LLO and OVA were added to macrophages, OVA protein could be detected throughout the entire cytosolic compartment within 30 minutes of bacterial uptake. Moreover, at least 50% of macrophages that had phagocytosed a single bacterium demonstrated release of OVA into the cytosol within 30 minutes following bacterial uptake. In some instances, OVA protein could be detected leaking from phagosomes into the cytosol as early as 10 minutes post-phagocytosis of bacteria.
- Since release of OVA into the cytosol occurs subsequent to degradation of theE. coli within macrophage phagosomes, it was possible that proteins contained within the bacteria were also partially degraded or inactivated before release into the cytosol. To examine whether full-length β-gal could be delivered to the cytosol of macrophages and retain its biological activity, E. coli expressing LLO and β-gal were added to macrophages to obtain an infection ratio of approximately one bacterium/macrophage. β-gal activity in the cytosol was then determined by staining macrophages with β-gal. Our data indicate that β-gal activity could be detected throughout the cytosol within 30 minutes following bacterial uptake. Following phagocytosis of E. coli expressing β-gal in the absence of LLO, β-gal activity was detected sequestered within phagosomes. β-gal is a 116 kD protein that functions as a 465 kD tetramer (33). Whether β-gal is associated as a tetramer prior to release into the cytosol is unknown, but these data indicate that at a minimum a 116 kD protein can be delivered to the cytosol of macrophages using the E. coli/LLO delivery system and still retain its enzymatic activity.
- Delivery of OVA to the MHC Class I Pathway for Antigen Presentation. Immunity to intracellular bacterial pathogens and viruses often requires the generation of cytotoxic T-lymphocytes (CTLs) that recognize and kill infected cells (13, 34, 35). Efficient processing and presentation of antigens to CTLs typically requires the endogenous synthesis of the antigen within the cytosol of the infected cell or introduction of the antigenic protein into the cytosol of an antigen presenting cell (APC) (36, 37). Once in the cytosol, proteases process the antigen to peptide epitopes which are subsequently presented on the surface of the APC in association with major histocompatibility (MHC) class I molecules for recognition by CD8+ CTLs (37-39).
- We wished to examine the ability ofE. coli expressing LLO and an antigenic protein to deliver the antigen to the cytosol of macrophages for processing and presentation on MHC class I molecules. E. coli expressing LLO and OVA were added to macrophages and the processing and presentation of a peptide epitope derived from OVA was accessed using the B3Z T-cell hybrid. B3Z is a LacZ-inducible CD8+ T-cell hybrid specific for OVA residues 257-264 (SIINFEKL, SEQ ID NO:6) presented on the murine Kb MHC class I molecule (27, 28). The presentation of the SIINFEKL epitope (SL8) to B3Z cells results in the induction of β-gal synthesis by B3Z. The amount of β-gal produced can be measured by the hydrolysis of the chromogenic substrate CPRG and is an indication of the amount of SL8/Kb complexes presented on the surface of APCs (27, 30). Bacteria were added to macrophages and phagocytosis allowed to proceed for one hour, followed by the removal of extracellular bacteria and addition of B3Z T-cells. As shown in FIG. 1, processing and presentation of SL8/Kb to B3Z T-cells occurred when E. coli expressing both LLO and OVA were added to macrophages. In this figure, the indicated number of E. coli were added to 1×105 Raw 309 Cr.1 APCs in each well of a 96-well plate. Following one hour of incubation at 37° C. in a 5% CO2/air atmosphere, extracellular bacteria were removed by washing with PBS and 1×105 B3Z T-cells were added to each well in medium containing 100 μg/ml gentamicin. Following 15 hours of incubation at 37° C. in a 5% CO2/air atmosphere, presentation of SL8/Kb to B3Z cells was assayed as described (27, 30) and indicated as an increase in the absorbance at 570 nm. E. coli strains added to APCs expressed LLO, DP-E3615 (◯); OVA, DP-E3616 ( ); or LLO and OVA, DP-E3617, (□). (▪) indicates the level of activation obtained when APCs were incubated with 90 nM synthetic SL8 and B3Z cells. Data presented is from triplicate groups of wells from one of several repeated experiments with identical results. As shown, antigen presentation could be detected with as few as 1 bacterium added/10 macrophages. At a ratio of 10 bacteria added/macrophage, which resulted in the phagocytosis of one to two bacteria/macrophage, the level of presentation was equivalent to the maximal activity achieved by incubating macrophages with a saturating dose (90 nM) of synthetic SL8 peptide. No presentation of SL8/Kb complex could be detected when E. coli expressing OVA in the absence of LLO were added to macrophages. Equivalent results were obtained when primary bone marrow and peritoneal derived macrophages were used in antigen presentation experiments. The decrease in absorbance seen when 107 and 108 LLO expressing bacteria were added was due to visible damage to the macrophages.
- Processing and Presentation of SL8/Kb Complex is Rapid. It has been previously demonstrated that OVA is efficiently processed and peptide/MHC complexes presented on the surface of APCs within two to four hours following delivery of OVA to the cytosol using alternative methods such as encapsulation in liposomes or scrape-loading (16, 20, 21). Data in FIG. 1 indicate that considerable processing and presentation of antigenic peptides can occur with as few as one bacterium added/macrophage. However, processing and presentation of antigen was allowed to occur for greater than 15 hours prior to measuring T-cell activation. It is possible that the time required for efficient processing of antigen has been altered by delivering protein to the cytosol using this method. We wished to examine the time necessary for antigen processing and presentation of peptide/MHC complexes when protein is delivered using the E. coli/LLO system.
- Paraformaldehyde fixation of macrophages prevents further phagocytosis of bacteria and has been shown to crosslink surface MHC class I molecules to associated β2-microglobulin (31). Thus, fixation stabilizes peptide/MHC complexes present on the cell surface and arrests any further processing and presentation of peptides. We examined the time required for antigen processing and presentation by fixing APCs with paraformaldehyde at varying intervals after addition of bacteria and measuring SL8/Kb presentation to B3Z T-cells. First, the effect on antigen presentation of fixing macrophages prior to the addition of bacteria was addressed (FIG. 2A). In FIG. 2A, 1×106 E. coli strain DP-E3617 expressing LLO and OVA were added to 1×105 IC-21 macrophages in each well of a 96-well plate. Processing and presentation of SL8/Kb was assayed as described in FIG. 1. Immediately prior to the addition of bacteria, APCs were either left untreated (Not Fixed) or fixed (Pre-Fixed) with 1% paraformaldehyde as described (31). Fixing APCs prior to the addition of bacteria completely abrogated the ability of macrophages to process and present SL8/Kb complex to B3Z T-cells, as evident by an equivalent response as that seen when no bacteria were added to the macrophages (FIG. 1).
- In FIG. 2B, the time requirement for processing and presentation of SL8/Kb complex was addressed. Here, 1×106 E. coli strain DP-E3617 expressing LLO and OVA were added to 1×105 IC-21 APCs in each well of a 96-well plate. Following one hour of incubation at 37° C. in a 5% CO2/air atmosphere, extracellular bacteria were removed by washing with PBS and APCs were either immediately fixed with 1% paraformaldehyde (1 hour) or incubated further in media containing 100 μg/ml gentamicin. At one hour intervals, APCs were fixed with 1% paraformaldehyde until all time points were completed. Following completion of the four hour time interval, APCs were washed with PBS and 1×105 B3Z T cells added to each well. Presentation of SL8/Kb was assayed as described above. Labels indicate the time elapsed post addition of bacteria prior to fixation of APCs. Dark shaded bars indicate samples to which E. coli strain DP-E3617 were added. Light shaded bar indicates samples to which no bacteria but 90 nM synthetic SL8 was added with B3Z cells. The (Not Fixed) samples received no fixation prior to the addition of B3Z cells. Data presented is from triplicate groups of wells from one of three experiments with identical results.
- Fixing APCs at one hour following the addition ofE. coli expressing LLO and OVA resulted in sufficient antigen presentation to yield activation of B3Z cells to a level slightly higher than those seen in the absence of fixing (compare 1 hour fixed to Not Fixed). The increased level of SL8/Kb presentation following fixation can be attributed to crosslinking of surface MHC class I molecules resulting in increased stability of peptide-MHC complexes (31). Consistent with previous studies of OVA delivery to APCs (16, 20, 21), the maximal presentation of SL8/Kb complex occurred when processing of OVA was allowed to continue for two hours prior to fixation. This level of SL8/Kb presentation was equivalent to that seen with the addition of 90 nM synthetic SL8 in the absence of fixation (FIG. 2B). Additional analysis indicated that fixing APCs later than two hours after addition of bacteria, resulted in a decreased level of SL8/Kb presentation (FIG. 2B, 3 and 4 hour time points). This is consistent with dissociation of surface peptide/MHC complexes prior to crosslinking MHC class I molecules by fixation (31). These data indicate that no delay in the processing and presentation of SL8/Kb complex occurred when OVA was delivered to the cytosol using the E. coli/LLO delivery system.
- The results of this example demonstrate thatE. coli expressing cytoplasmic LLO can be used to deliver a co-expressed protein to the cytosol of macrophages. The delivery of protein to macrophages was rapid and efficient with protein first appearing in the cytosol within ten minutes following bacterial uptake. Moreover, large enzymatically active proteins can be introduced into the cytosol using this method as demonstrated by the delivery of active β-gal. The mechanism of delivery may be as follows. Subsequent or concomitant to phagocytosis, the E. coli are killed and degraded within phagosomes causing the release of LLO and the target protein from the bacteria. LLO acts by forming large pores in the phagosomal membrane thus releasing the target protein into the cytosol. In any event, any protein that can be synthesized in E. coli can be delivered to the macrophage cytosol.
- LLO is an essential determinant of pathogenesis whose role is to mediate release ofL. monocytogenes from a phagosome. The biological properties of LLO make it well suited for use in our system. For example, LLO has an acidic pH optimum which facilitates its action in a phagosome (40, 41). However, it was unclear whether LLO released by degraded E. coli would retain its biological activity. The data presented here demonstrate that the amount of LLO expressed was sufficient to allow the rapid release of protein into the cytosol. Based on SDS-PAGE analysis of known quantities of purified LLO protein, we estimate approximately 1×105 molecules of LLO per E. coli cell. Using our disclosure, one can now determine how many molecules of LLO are actually needed to introduce a pore into a phagosome as described (42), where it was determined to take only approximately 50 molecules of streptolysin O, a homologous pore-forming cytolysin, to form a pore in red cell membranes. A second property of LLO is its relative lack of toxicity thought to be due to its proteolysis in the cytosol of host cells (43). Indeed, secretion by L. monocytogenes of a related pore-forming hemolysin, perfringolysin O, resulted in death of the infected cells (44). Other facultative intracellular pathogens, Shigellae, Salmonellae, and Yersiniae all induce macrophage apoptosis (14, 45), yet infection with L. monocytogenes is relatively benign (46). In the current study, even though we estimate each recombinant E. coli contained approximately 1×105 molecules of LLO, there was no evidence of toxicity until there were about 25 bacteria/macrophage.
- There are a number of advantages and applications of theE. coli/LLO delivery system. Many methodologies for delivering protein to the cytosol of macrophages require the prior purification of the protein to be delivered. With the E. coli/LLO mediated delivery of protein, no protein purification is required, only expression of the target protein in E. coli is necessary. Furthermore, with many alternative methods, delivery is restricted to minute amounts of protein or a limited number of cells and the in vivo delivery of protein can not be achieved (2). Using the E. coli/LLO system, high levels of protein can be delivered to the cytosol of virtually all of the cells in culture. In addition, by expressing protein under the control of inducible promoters, the level of protein produced and ultimately delivered to the cytosol of macrophages can be controlled. This system can be used in vivo and by expressing invasive determinants from other bacterial species, the E. coli may be modified to enter cells other than macrophages. Furthermore, this system has applications for the delivery of pathogen-specific protein antigens or DNA.
- The results of this example show that theE. coli/LLO system is particularly effective for the introduction of protein into the MHC class I pathway of antigen processing and presentation. We were able to detect antigen presentation with less than 1 bacterium/10 macrophages and observed a maximal response with as few as 1 to 2 bacteria/macrophage (FIG. 1). In addition, efficient processing and surface presentation of peptide/MHC complexes occurred rapidly, within 1-2 hours following addition of bacteria to macrophages (FIG. 2B). Delivery to the MHC class I pathway was enhanced greater than 4-logs compared to E. coli expressing OVA alone. This is a similar level of enhancement to that reported when OVA linked to beads was compared to soluble OVA for presentation with MHC class I molecules (47). It is clear from subsequent studies that the beads, like LLO, mediated disruption of the phagosome (21, 48). However, there was one report in which E. coli expressing OVA was able to deliver OVA to the MHC class I pathway (49). Here, delivery was proposed to occur by a non-conventional pathway involving extracellular peptide regurgitation of phagosomal processed antigens instead of transfer of protein from the phagosomal compartment to the cytosol. Nonetheless, our data clearly show undetectable levels of antigen presentation when E. coli lacking LLO yet expressing OVA to 20% of the total cellular protein were used to deliver OVA to macrophages. Perhaps the T-cells used in our studies were unable to detect presentation of SL8/Kb complexes, when E. Coli expressing OVA alone were used, because of inefficient processing and presentation via the non-conventional pathway. In the previous study, OVA was generated as fusions to Cr1 or LamB proteins. The efficiency of processing and presentation of epitopes from OVA has been shown to be dependent on the protein context surrounding the epitope (50, 51). Therefore, it is possible that the fusion proteins used in the previous study are processed more efficiently than the truncated OVA used in this report.
- Recently, anE. coli expression cloning strategy for the identification of CD4+ T cell-stimulating antigens has been reported (30). However, this method has not been successfully used to identify CD8+ CTL-stimulating antigens since proteins expressed in E. coli do not gain efficient access to the MHC class I pathway for antigen presentation. The results of this study indicate that the E. coli/LLO delivery system provides an expression cloning strategy for the identification of pathogen-specific CD8+ CTL-stimulating antigens. The identification of these pathogen-specific epitopes is an important step in the rational design of vaccine strategies against these infectious agents. These antigens are further characterized to determine the peptide epitopes recognized by CTLs, as well as the natural function the antigenic protein plays in the interaction of the pathogen and host cells.
- The efficiency of antigen delivery provides for theE. coli/LLO system to be used for the induction of CTLs in vivo. The efficient in vivo delivery of antigens to generate a protective immune response is a significant challenge in vaccine development. The use of bacterial vectors that have evolved to invade and replicate in mammalian cells such as Shigella (11, 12), Salmonella (8-10), and Listeria monocytogenes (52-55) are being explored as methods for the delivery of both protein antigens and DNA. Although these vehicles have had success in eliciting protective immune responses, the in vivo use of pathogenic bacteria has inherent risks. One strategy to overcome these obstacles has been to engineer attenuated E. coli that can invade and enter the cytosol of host cells for the delivery of macromolecules. E. coli deficient in the production of diaminopimelate (DAP), an essential cell wall component, undergo lysis during growth in the absence of DAP (56). DAP-minus E. coli carrying the 200 kb virulence plasmid pWR100 from Shigella flexneri have been engineered to deliver DNA to mammalian cells (11). These E. coli have the ability to invade cultured cells and enter the cytosol similar to S. flexneri, yet following brief replication, spontaneously lyse in the cytosol and allow for the delivery of DNA for subsequent expression in the host cell. However, the presence of the pWR100 virulence plasmid poses limitations on the suitability of this microbe for many applications; The rational design of safe delivery vectors is therefore of paramount importance when constructing new methodologies for in vivo delivery. Since the E. coli/LLO system does not contain any virulence associated determinants other than LLO, it is uniquely situated to safely deliver antigens to macrophages in vivo to generate a protective immune response.
- 1. Wong, T. K. & Neumann, E. (1982)Biochem. Biophys. Res. Commun. 107, 584-587.
- 2. Celis, J. E., ed. (1998) inCell Biology: a laboratory handbook, 2nd. ed., Vol. 4. (Acad Press, San Diego, Calif.).
- 3. Rozengurt, E., et al. (1975)Biochem. Biophys. Res. Commun. 67, 1581-1588.
- 4. Grant, N. J., Aunis, D., & Bader, M. F. (1987)Neuroscience 23, 1143-1155.
- 5. Vile, R. G., Tuszynski, A., & Castleden, S. (1996)Mol. Biotechnol. 5, 139-158.
- 6. Adams, S. E., & Kingsman, A. J. (1995)Pharm. Biotechnol. 6, 769-786.
- 7. Dachs, G. U., et al. (1997)Oncol. Res. 9, 313-325.
- 8. Darji, A., et al. (1997)Cell 91, 765-775.
- 9. Gentschev, I., et al. (1996)Gene 179, 133-140.
- 10. Hess, J., et al. (1996)Proc. Natl. Acad. Sci. U.S.A. 93, 1458-1463.
- 11. Courvalin, P., et al. (1995)C. R. Acad. Sci. III 318, 1207-1212.
- 12. Sizemore, D. R., Branstrom, A. A., & Sadoff, J. C. (1995)Science 270, 299-302.
- 13. Kaufmann, S. H. (1993)Annu. Rev. Immunol. 11, 129-163.
- 14. Finlay, B. B., & Cossart, P. (1997)Science 276, 718-725.
- 15. Portnoy, D. A., et al. (1992)Infect. Immun. 60, 1263-1267.
- 16. Lee, K. D., et al. (1996)J. Biol. Chem. 271, 7249-7252.
- 17. Darji, A., et al. (1997)Eur. J. Immunol. 27, 1353-1359.
- 18. Darji, A., et al. (1995)Eur. J. Immunol. 25, 2967-2971.
- 19. Mazzaccaro, R. J., et al. (1996)Proc. Natl. Acad. Sci. U.S.A. 93, 11786-11791.
- 20. Zhou, F., Watkins, S.C., & Huang, L. (1994)Immunobiology 190, 35-52.
- 21. Oh, Y. K., Harding, C. V., & Swanson, J. A. (1997)Vaccine 15, 511-518.
- 22. Darji, A., et al. (1995)J. Biotechnol. 43, 205-212.
- 23. Chang, A. C. Y., & Cohen, S. N. (1979)J. Bacteriol. 134, 1141-1156.
- 24. Linn, T., & St. Pierre, R. (1990)J. Bacteriol. 172, 1077-1084.
- 25. Sambrook, J., et al. (1989) inMolecular cloning: a laboratory manual, eds. Ford, N., Nolan, C. & Ferguson, M. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.)
- 26. Portnoy, D. A., Jacks, P. S., & Hinrichs, D. J. (1988)J. Exp. Med. 167, 1459-1471.
- 27. Sanderson, S., & Shastri, N. (1994)Int. Immunol. 6, 369-376.
- 28. Karttunen, J., et al. (1992)Proc. Natl. Acad. Sci. U.S.A. 89, 6020-6024.
- 29. Marquis, H., Goldfine, H., & Portnoy, D. A. (1997)J. Cell Biol. 137, 1381-1392.
- 30. Sanderson, S., Campbell, D. J., & Shastri, N. (1995)J. Exp. Med. 182, 1751-1757.
- 31. Rock, K. L., et al. (1992)J. Immunol. 148, 1451-1457.
- 32. Takahashi, N., Orita, T., & Hirose, M. (1995)Gene 161, 211-216.
- 33. Jacobson, R. H., et al. (1994)Nature 369, 761-766.
- 34. Kagi, D., et al. (1996)Annu. Rev. Immunol. 14, 207-232.
- 35. Singh, N., Agrawal, S., & Rastogi, A. K. (1997)Emerg. Infect. Dis. 3, 41-49.
- 36. Harding, C. V. (1996)J. Clin. Immunol. 16, 90-96.
- 37. York, I. A., & Rock, K. L. (1996)Annu. Rev. Immunol. 14, 369-396.
- 38. Craiu, A., et al. (1997)Proc. Natl. Acad. Sci. U.S.A. 94, 10850-10855.
- 39. Rock, K. L., et al. (1994)Cell 78, 761-771.
- 40. Geoffroy, C., et al. (1987)Infect. Immun. 55, 1641-1646.
- 41. Beauregard, K. E., et al. (1997)J. Exp. Med. 186, 1159-1163.
- 42. Sekiya, K., et al. (1993)J. Bacteriol. 175, 5953-5961.
- 43. Villanueva, M. S., Sijts, A. J., & Pamer, E. G. (1995)J. Immunol. 155, 5227-5233.
- 44. Jones, S., & Portnoy, D. A. (1994)Infect. Immun. 62, 5608-5613.
- 45. Ruckdeschel, K., et al. (1997)Infect. Immun. 65, 4813-4821.
- 46. Barsig, J., & Kaufmann, S. H. (1997)Infect. Immun. 65, 4075-4081.
- 47. Kovacsovics-Bankowski, M., et al. (1993)Proc. Natl. Acad. Sci. USA 90, 4942-4946.
- 48. Kovacsovics-Bankowski, M., & Rock, K. L. (1995)Science 267, 243-246.
- 49. Pfeifer, J. D)., et al. (1993)Nature 361, 359-362.
- 50. Svensson, M., et al. (1997)Behring Inst. Mitt. 98, 197-211.
- 51. Shastri, N., Serwold, T., & Gonzalez, F. (1995)J. Immunol. 155, 4339-4346.
- 52. Frankel, F. R., et al. (1995)J. Immunol. 155, 4775-4782.
- 53. Ikonomidis, G., et al. (1997)Vaccine 15, 433-440.
- 54. Shen, H., et al. (1995)Proc. Natl. Acad. Sci. U.S.A. 92, 3987-3991.
- 55. Pan, Z. K., et al. (1995)Nat. Med. 1, 471-477.
- 56. Patte, J. C. (1996) inBiosynthesis of Threonine and Lysine, eds. Neidhardt, F. C., et al. (ASM Press, Washington, D.C.), pp. 528-541.
- All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
-
1 6 1 34 DNA Listeria monocytogenes 1 ggaattccat atgaaggatg catctgcatt caat 34 2 33 DNA Listeria monocytogenes 2 cgggatcctt attattcgat tggattatct act 33 3 26 DNA Listeria monocytogenes 3 cgcgatatcc tctagaaata attttg 26 4 32 DNA Listeria monocytogenes 4 aggcgtcgac ggttaatacg accgggatcg ag 32 5 40 DNA Listeria monocytogenes 5 aggcgtcgac aggccttacg cgaaatacgg gcagacatgg 40 6 8 PRT murine 6 Ser Ile Ile Asn Phe Glu Lys Leu 1 5
Claims (12)
1. A nonvirulent bacterium comprising a first gene encoding a nonsecreted foreign cytolysin operably linked to a heterologous promoter and a second gene encoding a different foreign agent.
2. The bacterium of claim 1 , wherein the cytolysin is absent a functional signal sequence.
3. The bacterium of claim 1 , wherein the cytolysin is listeriolysin.
4. The bacterium of claim 1 , wherein the bacterium further comprises a third gene encoding an invasin and a fourth gene encoding an autolysin.
5. The bacterium of claim 1 , wherein the bacterium is a laboratory strain of E. coli.
6. The bacterium of claim 1 , wherein the foreign agent is therapeutic to a eukaryote.
7. A eukaryotic cell comprising the nonvirulent bacterium of claim 1 further comprising the foreign cytolysin.
8. The cell of claim 7 , wherein the cell is phagocytic, pathogenic or diseased cell.
9. A method for introducing a foreign agent into a eukaryotic cell comprising the step of contacting the cell with the bacterium of claim 1 under conditions whereby the agent enters the cell.
10. The method of claim 9 , wherein the bacterium is endocytosed into a vacuole of the cell, the bacterium undergoes lysis and the cytolysin mediates transfer of the agent from the vacuole to the cytosol of the cell.
11. A method of generating an immune response to a foreign antigenic agent, comprising the step of introducing the foreign antigenic agent into a cell of an patient by contacting the cell with a bacterium under conditions whereby the agent enters the cell,
said bacterium comprising a first gene encoding a nonsecreted foreign functional cytolysin operably linked to a heterologous promoter which expresses the cytolysin in the bacterium, and a second gene encoding the foreign antigenic agent, which is other than the cytolysin.
12. A method of generating an physiological response to a therapeutic agent, comprising the step of introducing the therapeutic agent into a cell of an patient by contacting the cell with a bacterium under conditions whereby the agent enters the cell,
said bacterium comprising a first gene encoding a nonsecreted foreign functional cytolysin operably linked to a heterologous promoter which expresses the cytolysin in the bacterium, and a second gene encoding the therapeutic agent, which is other than the cytolysin.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/627,452 US20040115221A1 (en) | 1998-08-13 | 2003-07-25 | Intracellular delivery vehicles |
US11/861,413 US20080166366A1 (en) | 1998-08-13 | 2007-09-26 | Intracellular Delivery Vehicles |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/133,914 US6004815A (en) | 1998-08-13 | 1998-08-13 | Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells |
US09/469,197 US6287556B1 (en) | 1998-08-13 | 1999-12-21 | Intracellular delivery vehicles |
US09/949,109 US6599502B2 (en) | 1998-08-13 | 2001-09-07 | Intracellular delivery vehicles |
US10/627,452 US20040115221A1 (en) | 1998-08-13 | 2003-07-25 | Intracellular delivery vehicles |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/949,109 Continuation US6599502B2 (en) | 1998-08-13 | 2001-09-07 | Intracellular delivery vehicles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/861,413 Continuation US20080166366A1 (en) | 1998-08-13 | 2007-09-26 | Intracellular Delivery Vehicles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040115221A1 true US20040115221A1 (en) | 2004-06-17 |
Family
ID=22460889
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/133,914 Expired - Lifetime US6004815A (en) | 1998-08-13 | 1998-08-13 | Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells |
US09/469,197 Expired - Lifetime US6287556B1 (en) | 1998-08-13 | 1999-12-21 | Intracellular delivery vehicles |
US09/949,109 Expired - Lifetime US6599502B2 (en) | 1998-08-13 | 2001-09-07 | Intracellular delivery vehicles |
US10/627,452 Abandoned US20040115221A1 (en) | 1998-08-13 | 2003-07-25 | Intracellular delivery vehicles |
US11/861,413 Abandoned US20080166366A1 (en) | 1998-08-13 | 2007-09-26 | Intracellular Delivery Vehicles |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/133,914 Expired - Lifetime US6004815A (en) | 1998-08-13 | 1998-08-13 | Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells |
US09/469,197 Expired - Lifetime US6287556B1 (en) | 1998-08-13 | 1999-12-21 | Intracellular delivery vehicles |
US09/949,109 Expired - Lifetime US6599502B2 (en) | 1998-08-13 | 2001-09-07 | Intracellular delivery vehicles |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/861,413 Abandoned US20080166366A1 (en) | 1998-08-13 | 2007-09-26 | Intracellular Delivery Vehicles |
Country Status (4)
Country | Link |
---|---|
US (5) | US6004815A (en) |
EP (1) | EP1105512A1 (en) |
AU (1) | AU5674099A (en) |
WO (1) | WO2000009733A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050118193A1 (en) * | 2003-09-17 | 2005-06-02 | The Regents Of The University Of California | Bacterial vectors and methods of use thereof |
US20050249748A1 (en) * | 2003-12-24 | 2005-11-10 | Dubensky Thomas W Jr | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US20100048418A1 (en) * | 2008-07-01 | 2010-02-25 | Jessica Flechtner | Antigen screening system |
US10859566B2 (en) | 2017-03-20 | 2020-12-08 | Genocea Biosciences, Inc. | Treatment methods |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030202980A1 (en) * | 1995-12-29 | 2003-10-30 | Caplan Michael J. | Methods and reagents for decreasing clinical reaction to allergy |
US6099848A (en) * | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
US7879977B2 (en) * | 1998-01-31 | 2011-02-01 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
EP2363478B1 (en) * | 1999-04-21 | 2019-07-24 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibiting the function of polynucleotide sequences |
US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
US8246945B2 (en) * | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
CA2403292C (en) * | 2000-04-06 | 2011-02-08 | Panacea Pharmaceuticals, Llc | Microbial delivery system |
US6872547B1 (en) * | 2000-10-11 | 2005-03-29 | Washington University | Functional balanced-lethal host-vector systems |
AUPR446801A0 (en) | 2001-04-18 | 2001-05-17 | University Of Queensland, The | Novel compositions and uses therefor |
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
US7396822B2 (en) * | 2001-05-24 | 2008-07-08 | Vaxiion Therapeutics, Inc. | Immunogenic minicells and methods of use |
US20030224369A1 (en) * | 2002-02-25 | 2003-12-04 | Surber Mark W. | Reverse screening and target identification with minicells |
US20030224444A1 (en) * | 2002-02-25 | 2003-12-04 | Sabbadini Roger A. | Antibodies to native conformations of membrane proteins |
US20030207833A1 (en) * | 2002-02-25 | 2003-11-06 | Neil Berkley | Pharmaceutical compositions with minicells |
US7425449B2 (en) * | 2002-04-30 | 2008-09-16 | The Regents Of The University Of California | Site specific Listeria integration vectors and methods for using the same |
US20040005700A1 (en) * | 2002-05-28 | 2004-01-08 | Surber Mark W. | Poroplasts |
AU2003240971A1 (en) * | 2002-05-29 | 2003-12-19 | Univ California | Attenuated listeria spp. and methods for using the same |
US20050214264A1 (en) * | 2002-12-13 | 2005-09-29 | Cosenza Lawrence W | Sacromastigophoric therapeutic agent delivery system |
US7771372B2 (en) * | 2003-01-03 | 2010-08-10 | Ekos Corporation | Ultrasonic catheter with axial energy field |
US7695725B2 (en) | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
EP1592441B1 (en) * | 2003-02-06 | 2012-04-11 | Aduro Biotech | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
CA2515298C (en) * | 2003-02-06 | 2014-04-08 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
US20090217882A1 (en) * | 2003-07-11 | 2009-09-03 | Dennis Jenkins | Dry Bed Agglomeration Process and Product Formed Thereby |
US20050147621A1 (en) * | 2003-10-10 | 2005-07-07 | Higgins Darren E. | Use of bacterial 5' untranslated regions for nucleic acid expression |
EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
GB0402131D0 (en) | 2004-01-30 | 2004-03-03 | Isis Innovation | Delivery method |
WO2006055024A2 (en) * | 2004-04-05 | 2006-05-26 | Vaxiion Therapeutics, Inc. | Minicells as vaccines |
EP1817061B1 (en) * | 2004-12-01 | 2011-07-27 | Aeras Global Tuberculosis Vaccine Foundation | Electroporation of mycobacterium and overexpression of antigens in mycobacteria |
GB0503509D0 (en) * | 2005-02-19 | 2005-03-30 | New Royal Holloway & Bedford | An improved delivery agent |
DE102005016234B4 (en) * | 2005-04-08 | 2008-05-15 | Tgc Biomics Gmbh | Method of introducing exogenous antigen into the MHC I presentation pathway of cells |
EP1764107A1 (en) * | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides |
EP3042958B1 (en) | 2006-02-21 | 2019-06-19 | President and Fellows of Harvard College | Methods and compositions for identifying antigens |
HUE033007T2 (en) * | 2006-06-23 | 2017-11-28 | Engeneic Molecular Delivery Pty Ltd | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
WO2008066774A2 (en) | 2006-11-22 | 2008-06-05 | The Regents Of The University Of California | INTERFERON-β PRODUCTION MODULATING LISTERIA STRAINS AND METHODS FOR USING SAME |
ES2331271B1 (en) * | 2007-06-29 | 2010-10-14 | Universidad Del Pais Vasco | METHOD FOR THE INTERNALIZATION OF NON INVASIVE BACTERIA IN EUCARIOT CELLS. |
US8029740B2 (en) | 2008-07-11 | 2011-10-04 | The Invention Science Fund I, Llc | Event-triggered self-sterilization of article surfaces |
US8366652B2 (en) | 2007-08-17 | 2013-02-05 | The Invention Science Fund I, Llc | Systems, devices, and methods including infection-fighting and monitoring shunts |
US9005263B2 (en) | 2007-08-17 | 2015-04-14 | The Invention Science Fund I, Llc | System, devices, and methods including actively-controllable sterilizing excitation delivery implants |
EP2231257A4 (en) | 2007-12-24 | 2013-11-06 | Univ Queensland | Coating method |
WO2009097660A1 (en) | 2008-02-07 | 2009-08-13 | The University Of Queensland | Patch production |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
WO2009143167A2 (en) | 2008-05-19 | 2009-11-26 | Advaxis | Dual delivery system for heterologous antigens |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
WO2009140735A1 (en) * | 2008-05-23 | 2009-11-26 | The University Of Queensland | Analyte detection by microneedle patch with analyte selective reagents. |
CA2726293C (en) * | 2008-06-03 | 2017-02-28 | University Of Maryland, Baltimore | Non-hemolytic clya for excretion of proteins |
US20110295090A1 (en) | 2008-12-04 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems, devices, and methods including implantable devices with anti-microbial properties |
CN102325563A (en) | 2008-12-22 | 2012-01-18 | 昆士兰大学 | Patch production |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US9943673B2 (en) | 2010-07-14 | 2018-04-17 | Vaxxas Pty Limited | Patch applying apparatus |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
WO2012138377A2 (en) | 2010-10-01 | 2012-10-11 | Trustees Of The University Of Pennsylvania | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
CN103328499A (en) | 2010-11-01 | 2013-09-25 | 悉尼科技大学 | Immune-modulating agents and uses therefor |
WO2012096926A2 (en) * | 2011-01-10 | 2012-07-19 | President And Fellows Of Harvard College | Method for delivering agents into cells using bacterial toxins |
EP2675474B1 (en) | 2011-02-15 | 2019-01-16 | Vaxiion Therapeutics, LLC | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
CN103687611A (en) | 2011-03-11 | 2014-03-26 | 阿德瓦希斯公司 | Listeria-based adjuvants |
WO2013053022A1 (en) | 2011-10-12 | 2013-04-18 | The University Of Queensland | Delivery device |
US9101678B2 (en) | 2011-11-03 | 2015-08-11 | Elwha Llc | Heat-sanitization of surfaces |
WO2013096926A1 (en) | 2011-12-22 | 2013-06-27 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
US8956873B2 (en) | 2012-01-13 | 2015-02-17 | Bell Biosystems, Inc. | Host cells with artificial endosymbionts |
US8828681B2 (en) | 2012-01-13 | 2014-09-09 | Bell Biosystems, Inc. | Host cells with artificial endosymbionts |
US10076579B2 (en) | 2012-01-13 | 2018-09-18 | Bell Biosystems, Inc. | Host cells with artificial endosymbionts |
US9023612B2 (en) | 2012-01-13 | 2015-05-05 | Bell Biosystems, Inc. | Eukaryotic cells with artificial endosymbionts for multimodal detection |
JP2015509501A (en) | 2012-02-23 | 2015-03-30 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Modified microbial toxin receptor for delivering agents to cells |
SG10201700392UA (en) | 2012-03-12 | 2017-03-30 | Advaxis Inc | Suppressor cell function inhibition following listeria vaccine treatment |
LT2928476T (en) | 2012-12-07 | 2018-05-25 | Glycomimetics, Inc. | Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells |
WO2014145785A1 (en) | 2013-03-15 | 2014-09-18 | Bell Biosystems, Llc | Host cells with artificial endosymbionts |
CN106164268A (en) | 2013-09-03 | 2016-11-23 | 贝尔生物系统公司 | The host cell utilizing artificial endosymbiont is modified |
EP3020816A1 (en) * | 2014-11-11 | 2016-05-18 | University College Cork | Bacterial mediated gene therapy |
SI3227310T1 (en) | 2014-12-03 | 2019-11-29 | Glycomimetics Inc | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
CA2975275C (en) | 2015-02-02 | 2023-08-29 | Vaxxas Pty Limited | Microprojection array applicator and method |
WO2017045031A1 (en) | 2015-09-18 | 2017-03-23 | Vaxxas Pty Limited | Microprojection arrays with microprojections having large surface area profiles |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
JP2019524791A (en) | 2016-08-08 | 2019-09-05 | グリコミメティクス, インコーポレイテッド | Combinations of T cell checkpoint inhibitors with inhibitors of E-selectin or inhibitors of CXCR4 or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
KR20240046288A (en) | 2016-10-07 | 2024-04-08 | 글리코미메틱스, 인크. | Highly potent multimeric e-selectin antagonists |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
CA3054605A1 (en) | 2017-03-15 | 2018-09-20 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
EP4306803A3 (en) | 2017-03-31 | 2024-04-10 | Vaxxas Pty Limited | Device and method for coating surfaces |
US11175128B2 (en) | 2017-06-13 | 2021-11-16 | Vaxxas Pty Limited | Quality control of substrate coatings |
AU2018309562A1 (en) | 2017-08-04 | 2020-02-20 | Vaxxas Pty Limited | Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP) |
WO2019108750A1 (en) | 2017-11-30 | 2019-06-06 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
JP7304863B2 (en) | 2017-12-29 | 2023-07-07 | グリコミメティクス, インコーポレイテッド | Heterobifunctional inhibitors of E-selectin and galectin-3 |
US11707474B2 (en) | 2018-03-05 | 2023-07-25 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
CN110408634B (en) * | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | Non-integrated listeria vaccine and anti-tumor immune response method |
JP2022512897A (en) | 2018-10-29 | 2022-02-07 | ジェノセア バイオサイエンシーズ, インコーポレイテッド | Method of treatment |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2023086969A2 (en) | 2021-11-12 | 2023-05-19 | Ichor Medical Systems Inc. | Treatment methods |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877159A (en) * | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4888170A (en) * | 1981-10-22 | 1989-12-19 | Research Corporation | Vaccines obtained from antigenic gene products of recombinant genes |
US5387744A (en) * | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
US5294441A (en) * | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
US5855880A (en) * | 1987-06-04 | 1999-01-05 | Washington University | Avirulent microbes and uses therefor |
DK0465560T3 (en) * | 1989-03-31 | 1996-10-28 | Univ Washington | Vaccines containing avirulent phoP-type microorganisms |
NO175188C (en) * | 1990-06-27 | 1994-09-14 | Sjur Olsnes | Process for Preparing a Peptide Conjugate with the ability to penetrate cell cytosol |
US5830702A (en) * | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
US5824538A (en) * | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
US5981182A (en) * | 1997-03-13 | 1999-11-09 | Albert Einstein College Of Medicine Of Yeshiva University | Vector constructs for the selection and identification of open reading frames |
-
1998
- 1998-08-13 US US09/133,914 patent/US6004815A/en not_active Expired - Lifetime
-
1999
- 1999-08-13 AU AU56740/99A patent/AU5674099A/en not_active Abandoned
- 1999-08-13 WO PCT/US1999/018466 patent/WO2000009733A1/en not_active Application Discontinuation
- 1999-08-13 EP EP99943697A patent/EP1105512A1/en not_active Withdrawn
- 1999-12-21 US US09/469,197 patent/US6287556B1/en not_active Expired - Lifetime
-
2001
- 2001-09-07 US US09/949,109 patent/US6599502B2/en not_active Expired - Lifetime
-
2003
- 2003-07-25 US US10/627,452 patent/US20040115221A1/en not_active Abandoned
-
2007
- 2007-09-26 US US11/861,413 patent/US20080166366A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877159A (en) * | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050118193A1 (en) * | 2003-09-17 | 2005-06-02 | The Regents Of The University Of California | Bacterial vectors and methods of use thereof |
US7390646B2 (en) | 2003-09-17 | 2008-06-24 | The Regents Of The University Of California | Bacterial vectors and methods of use thereof |
US20050249748A1 (en) * | 2003-12-24 | 2005-11-10 | Dubensky Thomas W Jr | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US20100048418A1 (en) * | 2008-07-01 | 2010-02-25 | Jessica Flechtner | Antigen screening system |
US8313894B2 (en) | 2008-07-01 | 2012-11-20 | Genocea Biosciences, Inc. | Antigen screening system |
US9045791B2 (en) | 2008-07-01 | 2015-06-02 | Genocea Biosciences, Inc. | Antigen screening system |
US9873870B2 (en) | 2008-07-01 | 2018-01-23 | Genocea Biosciences, Inc. | Antigen screening system |
US10570387B2 (en) | 2008-07-01 | 2020-02-25 | Genocea Biosciences, Inc. | Antigen screening system |
US11162093B2 (en) | 2008-07-01 | 2021-11-02 | Genocea Biosciences, Inc. | Antigen screening system |
US10859566B2 (en) | 2017-03-20 | 2020-12-08 | Genocea Biosciences, Inc. | Treatment methods |
Also Published As
Publication number | Publication date |
---|---|
US20020142007A1 (en) | 2002-10-03 |
AU5674099A (en) | 2000-03-06 |
EP1105512A1 (en) | 2001-06-13 |
US6004815A (en) | 1999-12-21 |
US6599502B2 (en) | 2003-07-29 |
US6287556B1 (en) | 2001-09-11 |
WO2000009733A1 (en) | 2000-02-24 |
US20080166366A1 (en) | 2008-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6287556B1 (en) | Intracellular delivery vehicles | |
Higgins et al. | Delivery of protein to the cytosol of macrophages using Escherichia coli K‐12 | |
Trülzsch et al. | Contribution of the major secreted yops of Yersinia enterocolitica O: 8 to pathogenicity in the mouse infection model | |
Page et al. | The secreted IpaB and IpaC invasins and their cytoplasmic chaperone IpgC are required for intercellular dissemination of Shigella flexneri | |
US8093025B2 (en) | Bacterial vector | |
Coombes et al. | Expression and secretion of Salmonella pathogenicity island-2 virulence genes in response to acidification exhibit differential requirements of a functional type III secretion apparatus and SsaL | |
Lee et al. | OmpR regulates the two-component system SsrA-SsrB in Salmonella pathogenicity island 2 | |
Lee et al. | Salmonella type III secretion‐associated chaperones confer secretion‐pathway specificity | |
Gründling et al. | Requirement of the Listeria monocytogenes broad-range phospholipase PC-PLC during infection of human epithelial cells | |
US20050147621A1 (en) | Use of bacterial 5' untranslated regions for nucleic acid expression | |
Lee et al. | A program of Yersinia enterocolitica type III secretion reactions is activated by specific signals | |
Cornells | Type III secretion: a bacterial device for close combat with cells of their eukaryotic host | |
Bronstein et al. | InvB is a type III secretion chaperone specific for SspA | |
Norris et al. | The Burkholderia pseudomallei Δ asd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice | |
Trülzsch et al. | Analysis of chaperone-dependent Yop secretion/translocation and effector function using a mini-virulence plasmid of Yersinia enterocolitica | |
Walker et al. | Intracellular delivery of biologic therapeutics by bacterial secretion systems | |
CZ20031378A3 (en) | Method for gene expression within a bacterial cell, method for inducing immune response in a host and protein expression system | |
WO2008110653A1 (en) | Antibody producing microorganism, elements required to obtain same, resulting antibodies, therapeutic compositions and use of thereof | |
Husseiny et al. | Recombinant vaccines based on translocated effector proteins of Salmonella Pathogenicity Island 2 | |
US20040147719A1 (en) | Type III bacterial strains for use in medicine | |
Igwe et al. | Concomitant cytosolic delivery of two immunodominant listerial antigens by Salmonella enterica serovar typhimurium confers superior protection against murine listeriosis | |
Li et al. | Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunity | |
Ceragioli et al. | Phagocytosis, germination and killing of Bacillus subtilis spores presenting heterologous antigens in human macrophages | |
Silva et al. | Attenuation of bacterial virulence by quorum sensing-regulated lysis | |
Sundberg et al. | TyeA of Yersinia pseudotuberculosis is involved in regulation of Yop expression and is required for polarized translocation of Yop effectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE, CALI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PORTNOY, DANIEL A.;HIGGINS, DARREN E.;REEL/FRAME:014340/0111 Effective date: 19980812 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |